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“Nothing in life is to be feared, it is only to be understood. 
Now is the time to understand more, so that we may fear less.” 
― Marie Curie 
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3’UTR  three prime untranslated region 
5’UTR  five prime untranslated region 
A  adenine  
ADC  adenocarcinoma 
ADSQ  adenosquamous cell carcinoma 
ATP  adenosine triphosphate 
bp  base pairs 
C  cytosine 
CI  confidence interval 
CNB  core needle biopsy 
CNV  copy number variation 
COSMIC the Catalogue of Somatic Mutations in Cancer 
dbSNP  the Single Nucleotide Polymorphism Database 
DNA  deoxyribonucleic acid 
DNMT DNA  methyl transferase 
EMT  epithelial-mesenchymal transition 
Eph  ephrin receptor 
FDA  the US Food and Drug Administration 
FFPE  formalin-fixed, paraffin-embedded 
FF  fresh frozen 
FNA  fine needle aspiration 
G  guanine 
GTPase small guanosine triphosphatase 
HDAC  histone deacetylase 
HR  hazard ratio 
IARC  the International Agency for Research on Cancer 
IHC  Immunohistochemical/immunohistochemistry 
LCC  large cell carcinoma 
LOH  loss of heterozygosity 
MM  malignant mesothelioma 
miRNA micro-RNA 
MPM  malignant pleural mesothelioma 
mRNA  messenger-RNA 
mtDNA mitochondrial DNA 
ncRNA non-coding RNA 
NGS  next generation sequencing 
NSCLC non-small cell lung cancer 
NOS  not otherwise specified 
OS  overall survival 
PCR  polymerase chain reaction 
PGM  Personal Genome Machine 
PFS  progression free survival 
RNA  ribonucleic acid 
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ROS  reactive oxygen species 
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rRNA  ribosomal RNA 
RTK  receptor tyrosine kinase 
SCC  squamous cell carcinoma 
SCLC  small cell lung cancer 
SNP  single nucleotide polymorphism 
T  thymine 
SNV  single nucleotide variant 
TKI  tyrosine kinase inhibitor 
TSG  third generation sequencing 
WHO  the World Health Organization 
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Lung cancer is a common cancer with a poor prognosis. During the last decade, 
prognostic and predictive molecular markers for lung cancer have become available and 
treatment options have also multiplied. Targeted treatments have been developed aimed at 
distinct aberrant molecules driving the tumorigenesis. Thus, it is important to clarify the 
molecular characteristics of a tumor if one wishes to optimize the therapy. The currently 
available targeted therapies as well as further development in this field would be aided by 
the identification of (novel) significant markers and understanding how their incidence is 
associated with clinical characteristics. The aim of this thesis work was to examine known 
and novel molecular markers, more specifically mutations in selected genes which could be 
potential molecular markers of cancer, and to link these characteristics with clinical data in 
Finnish lung cancer patients. Thus, mutations were studied in genes encoding ephrin 
receptors, EGFR, and 22 other lung cancer related genes. In addition, protein coding 
genomic regions, i.e. exons, were studied to determine whether there were mutations 
associated with asbestos-exposure. 
The study material consisted of more than 600 patients, their tumor specimens and 
clinical data. The majority of the specimens were formalin-fixed, paraffin-embedded non-
small cell lung cancer (NSCLC) and malignant mesothelioma (MM) samples. Most of the 
specimens were subjected to next generation sequencing (NGS); the suitability of this 
technology in cancer diagnostics was also assessed. In particular, targeted and exome 
sequencing NGS methods were used with sequencing being performed on Illumina and Ion 
Torrent platforms. In addition, PCR-based mutation testing was used, and capillary 
sequencing being applied for validation purposes. 
Mutations in ephrin receptor genes were common; 18 % of the patients carried one or 
more novel mutation. In MM, in particular EPHB1 was found to be mutated. The mutations 
did not associate with any particular clinical characteristic and they were found often 
concurrently with known pathogenic driver mutations, which points to a probable passenger 
mutation nature for these ephrin receptor mutations. However, when considering their 
diverse role in cellular function, as well as their oncogenic and tumor suppressive properties, 
therapeutically they may represent a very intriguing group of molecules. Thus, it would be 
important to clarify the significance of these alterations, especially at the mutation level. 
Clinically significant EGFR mutations were found in 11 % of tumors from NSCLC 
patients. The mutations were associated with adenocarcinoma histology, female gender and 
never-smoking status, as has been reported in previous studies. The incidence of EGFR 
mutations resembled that described in previous studies conducted on other Western patients. 
In the study comparing specimens from asbestos-exposed and non-exposed lung cancer, 
eight candidate genes (BAP1, COPG1, INPP4A, MBD1, SDK1, SEMA5B, TTLL6 and 
XAB2) were found to be recurrently mutated exclusively in the asbestos-exposed patients. 
Candidate genes included those involved in cellular oxidative stress. Mutations in BAP1 
and COPG1 were found exclusively in MM. BAP1 mutations and one SDK1 mutation were 
validated to be of somatic origin. 
Screening of hot spot regions in 22 genes related to lung cancer revealed TP53 and KRAS 
as the most frequently mutated genes, being mutated in 46 % and 26 % of the NSCLC 
patients, respectively. In particular, TP53 mutations were found to co-occur recurrently with 
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other mutations, also with pathogenic EGFR and KRAS mutations. Of the 425 patients, 77 
% carried one or more mutations. Statistically significant associations were found between 
the following mutated genes and clinical characteristics: TP53 and PIK3CA and squamous 
cell carcinoma, KRAS and adenocarcinoma, and CTNNB1 and light ex-smoking status. The 
mutation profile was rather similar to that described in Western NSCLC patients with some 
exceptions, such as the higher BRAF mutation and lower STK11 mutation frequency. 
The clinically significant mutations in Finnish NSCLC patients seem to resemble those 
detected in other Western patients. However, some differences can be found. Mutations in 
ephrin receptor genes are common and found often with other mutations. There seem to be 
molecular differences between asbestos-exposed and non-exposed lung cancers. However, 
the well-established lung cancer-related, pathogenic clinically relevant mutations, such as 
EGFR and KRAS, do not seem to be associated with asbestos-exposure. Finally, the 
application of NGS technology proved to be very suitable for cancer diagnostics. One major 
advantage of this technology is the possibility to test for different alterations in multiple 





Keuhkosyöpä on yleinen ja huonoennusteinen syöpä. Keuhkosyövän taudinkulun 
ennusteeseen (prognostinen) ja hoitovasteen ennusteeseen (prediktiivinen) vaikuttavista 
molekulaarisista markkereista tiedetään yhä enemmän, ja sen myötä syövän hoito on 
muuttunut. Käytössä on hoitomuotoja, jotka kohdentuvat tiettyyn syövän taustalla olevaan 
muuttuneeseen perimän molekyyliin. Kasvaimen molekulaaristen ominaisuuksien 
tunteminen mahdollistaa parhaan nykyaikaisen hoidon. Kohdennettujen hoitojen edelleen 
kehittäminen edellyttää tutkimusta merkittävien poikkeamien tunnistamiseksi, 
esiintyvyyden selvittämiseksi ja niiden yhteydestä taudin kliinis-patologisiin omaisuuksiin. 
Tämän väitöskirjatyön tavoitteena oli tutkia valikoitujen geenien uusia ja jo tunnettuja 
molekulaarisia markkereita, tarkemmin ottaen mutaatioita, suomalaisilla 
keuhkosyöpäpotilailla, ja niiden yhteyttä potilaiden kliinisiin ominaisuuksiin. Mutaatioita 
tutkittiin seuraavissa geeneissä: efriinireseptorit, EGFR, ja 22 keuhkosyöpään liittyvää 
geeniä. Lisäksi tutkittiin koko genomin proteiinia koodaavilta alueilta, eli eksoneista, 
asbestialtistukseen liittyviä mutaatioita. 
Materiaalina tutkimuksessa oli yhteensä yli 600 potilaan aineisto sisältäen 
tuumorinäytteet ja potilaiden kliiniset tiedot. Valtaosa näytteistä oli formaliinilla fiksattuja, 
parafiiniin valettuja ei-pienisolukeuhkosyöpä (NSCLC)- ja mesotelioomanäytteitä (MM). 
Tutkimuksessa käytettiin pääsääntöisesti uuden polven sekvensointimenetelmiä (NGS), 
joiden luotettavuutta ja sopivuutta syöpädiagnostiikassa arvioitiin. NGS-menetelmistä 
käytettiin kohdennettua ja eksomisekvensointia. Sekvensoinnit tehtiin Illumina ja Ion 
Torrent-teknologioilla. Lisäksi käytettiin PCR-perusteista mutaatiotestausta, ja 
kapillaarisekvensointia tuloksien validoinnissa. 
Mutaatiot efriinireseptori-geeneissä olivat yleisiä; 18 % potilaista todettiin vähintään 
yksi uusi mutaatio. Erityisesti EPHB1-mutaatiot toistuivat MM-potilailla. Mutaatiot eivät 
olleet kytköksissä mihinkään tiettyyn kliiniseen ominaisuuteen, ja ne esiintyivät usein 
yhdessä tunnettujen, patogeenisten aloitusmutaatioiden kanssa, mikä viittaa 
efriinireseptorimutaatioiden matkustajamutaatio-luonteeseen. Huomioiden 
efriinireseptorien monimuotoisen roolin solun toiminnassa, ja niiden sekä onkogeenisen ja 
tuumorisuppressiivisen potentiaalin, ovat ne hoidollisesti hyvin kiinnostava proteiiniryhmä. 
Siten niiden poikkeamien laajempi tunteminen myös mutaatiotasolla olisi tärkeää. 
Kliinisesti merkittäviä EGFR-geenin mutaatioita löydettiin 11 % NSCLC-potilaista. 
Mutaatiot olivat kytköksissä adenokarsinooma-histologiaan, naissukupuoleen ja 
tupakoimattomuuteen, kuten aiemmissa tutkimuksissa on kuvattu. EGFR-mutaatioiden 
esiintyminen suomalaisilla potilailla muistutti vahvasti mutaatioprofiilia, joka niin ikään on 
aiemmin kuvattu länsimaalaisissa potilasaineistoissa. 
Asbestialtistuneen ja altistumattoman keuhkosyövän vertailututkimuksessa löysimme 
kahdeksan kandidaattigeeniä (BAP1, COPG1, INPP4A, MBD1, SDK1, SEMA5B, TTLL6 ja 
XAB2), jotka olivat toistuvasti mutatoituneet vain asbestialtistuneilla potilailla. 
Kandidaattigeenit sisälsivät mm. solun hapetusstressiin liittyviä geenejä. BAP1 ja COPG1-
mutaatiot löytyivät yksinomaan MM-näytteistä. BAP1-mutaatiot ja yksi SDK1-mutaatio 
validoitiin somaattisiksi. 
Keuhkosyöpään liittyvien 22 geenin ns. hot spot-alueiden mutaatiokartoitus paljasti 
TP53 (46 %) ja KRAS-geenit (26 %) aineistomme NSCLC-potilailla yleisimmin 
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mutatoituneiksi. Erityisesti TP53-mutaatiot esiintyivät toistuvasti useiden muiden 
mutaatioiden kanssa, myös patogeenisten, keuhkosyöpään liittyvien EGFR ja KRAS-
mutaatioiden kanssa. Noin kolmella neljästä (77 %) NSCLC-potilaista (n=425) ilmeni 
vähintään yksi mutaatio. Tilastollisesti merkittäviä yhteyksiä löydettiin seuraavien 
geenimutaatioiden ja kliinis-patologisten ominaisuuksien välillä: TP53 ja PIK3CA ja 
levyepiteelikarsinooma, KRAS ja adenokarsinooma, sekä CTNNB1 ja kevyt 
tupakointihistoria. Mutaatioprofiili oli muutamin poikkeuksin hyvin samankaltainen kuin 
länsimaalaisilla potilailla aiemmin kuvattu. Tässä tutkimuksessa löydettiin korkeampi 
BRAF-mutaatio- ja matalampi STK11-mutaatiofrekvessi. 
Suomalaisten NSCLC-potilaiden mutaatioprofiili muistuttaa vahvasti länsimaisissa 
potilasaineistoissa kuvattuja. Joitakin poikkeuksia kuitenkin löytyy. Asbestialtistuneen ja 
altistumattoman keuhkosyövän välillä vaikuttaa olevan molekulaarisia eroavaisuuksia. 
Hyvin tunnetut patogeeniset kliinisesti merkittävät mutaatiot, kuten EGFR and KRAS, eivät 
kuitenkaan näytä liittyvän asbestialtistukseen. Efriinireseptorien mutaatiot ovat yleisiä, ja 
ne esiintyvät usein muiden poikkeamien kanssa. Lisäksi, NGS-menetelmät sopivat hyvin 
syöpädiagnostiikkaan. Niiden ehdoton etu on mahdollisuus testata monenlaisia poikkeamia 





Cancer is one of the leading disease-burdens and a major cause of global mortality. It is 
characterized by rapid and uncontrolled cell growth. Cancer originates from an abnormal 
cell that has gained a growth advantage and managed to escape from the normal control 
system. Cancer may originate in any tissue, can grow in any part of the body, and spread to 
adjacent tissues or even to distant organs through metastases. One fundamental feature of 
cancer is that the malignant cells harbor an accumulation of genetic and epigenetic 
instabilities. These genetic alterations can be structural or numerical chromosome changes, 
smaller DNA sequence alterations, or epigenetic changes. However, only a minority of those 
alterations can actually drive tumorigenesis; these are considered as driver alterations, while 
other alterations are passenger events. 
Conventionally cancer is treated with surgery, chemo- and radiotherapy. Nowadays, 
there are multiple targeted treatment options available for different cancer types. These 
treatments tend to be targeted against a certain aberrant molecule that is involved in cancer 
development and/or progression. However, unfortunately after a preliminary good response, 
in general, resistance develops to all of these treatments. The resistance may be attributable 
to several mechanisms, but it is believed that genetic alterations play a crucial role. Thus, it 
is important to characterize tumor molecular markers in detail, and to distinguish the 
significant driver alterations from the numerous passengers. 
As our understanding of molecular basis of cancer has deepened, the tumor 
classifications have also supplemented details of location and cell morphology to include 
their molecular features. The revolution of genetic markers, their validation along with 
improvements of genetic diagnostics tools, has brought genomics-based cancer medicine 
into the clinics. The increasing numbers of targeted treatments demand that there are 
efficient tools for pinpointing those patients who will benefit from the targeted therapy. The 
first next generation sequencing (NGS) methods were introduced approximately a decade 
ago. After multiple and various development steps, improvements and validations, NGS has 
been approved for clinical use. They are particularly useful in diagnostics, as they enable to 
test in a time and cost-efficient manner multiple distinct alterations simultaneously from a 
small starting material. 
Lung cancer is a fatal malignant disease with a very high incidence all around the world. 
Lung cancer may develop in any part of the lung. The most important cause of lung cancer 
is tobacco smoke. According to its histological features, lung cancer can be divided into two 
major groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 
NSCLCs are the most common form, accounting for 85 % of all lung cancer cases. NSCLCs 
can be further divided into smaller subgroups based on cell morphology and molecular 
features. The characteristic molecular alterations encountered in adenocarcinoma tumors 
are especially used in the clinics, as some of these alterations may predict a response to 
targeted treatment. 
Malignant mesothelioma (MM) is rarer, but a frequently fatal cancer associated strongly 
with asbestos exposure. MM originates in the mesothelium, the cell lining of internal organs. 
Most commonly MM develops in the linings of the lungs (pleura), abdomen (peritoneum) 
and heart (pericardium), in decreasing frequency. The molecular changes occurring in MMs 
are not as well-established as those in NSCLC, particularly the alterations associated with 
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asbestos-exposure (if any) remain obscure. The development of targeted therapies and 
predictive biomarkers would be one way to improve the outcome in MM. 
It has become clear that ethnicity influences molecular changes. Thus, it was deemed 
relevant to study molecular markers in a national Finnish lung cancer cohort since the 
Finnish population has a history of genetic isolation. Therefore, this thesis focused on the 
investigation of molecular markers, i.e. mutations in DNA, in Finnish NSCLCs and MMs, 
especially their association with clinicopathological characteristics of the patients. The main 





Cancer is a complex malignant disease, expanding from an altered cell after its clonal 
expansion. The cell needs to possess certain genetic and epigenetic characteristics that 
confer on it an evolutionary benefit to undergo uncontrolled growth. Those genetic 
alterations may occur either in proto-oncogenes encoding the proteins involved in cell 
proliferation, differentiation, invasion and growth triggering an activation of those genes, 
or in tumor suppressor genes, which encode the proteins regulating cell cycle or DNA repair, 
causing their inactivation. In both cases, the alterations confer a growth advantage. In 
general, both alleles in the homologous chromosomes of tumor suppressor genes need to be 
altered, as they commonly act in a recessive manner. This “two-hit hypothesis” was first 
suggested by Knudson (1971) for retinoblastoma. On the contrary, proto-oncogenes are 
commonly dominant, thus an alteration in one allele can cause a gain-of-function change, 
and proto-oncogenes become transformed into oncogenes with pathogenic features. 
In the review of Vogelstein et al. (2013) it was estimated that there may be from two to 
eight alterations present in a tumor that can actually drive the tumorigenesis (driver 
alterations), for instance, by altering pathways involved in cell fate, survival or genome 
maintenance. The others changes are considered as passenger alterations. Mutations in 
oncogenes are prone to occur in certain amino acid residues, whereas mutations in tumor 
suppressors occur in multiple distinct positions along the gene. It is known that lung cancer 
cells very frequently harbor somatic mutations; the median number of non-synonymous 
mutations being around 150 in a tumor (Vogelstein et al., 2013). 
Genetic changes may occur at different levels, from small DNA sequence alterations to 
larger structural and numerical chromosome changes. If alterations occur in the protein-
coding regions of the genome, i.e. exons, they may lead to the production of altered 
protein(s) encoded by a gene. Gene expression is regulated by several mechanisms that can 
also be altered. Numerous proteins are involved in the cellular signaling pathways that 
regulate many crucial cellular functions, such as programmed cell death, i.e. apoptosis, 
differentiation, proliferation and migration. It is these altered proteins and signaling 
pathways that serve as targets for novel therapeutic agents, such as monoclonal antibodies 
and small molecule inhibitors (reviewed in Ciavarella et al., 2010). The newest targeted 
agents are able to inhibit oncogenic features while preserving normal cellular function 
(Ciavarella et al., 2010).  
Hanahan and Weinberg (2011) have described eight distinct hallmarks, known as the 
“Hallmarks of cancer”, that a normal cell needs to acquire if it is to become malignant: 1) 
self-sufficiency in growth signals, 2) insensitivity to antigrowth signals, 3) evasion of 
apoptosis, 4) limitless replication potential, 5) sustained angiogenesis, 6) tissue invasion and 
metastasis, 7) reprogramming of energy metabolism, and 8) evasion of immune destruction. 
Genomic instability and inflammatory reactions of (pre)malignant lesions promote and 
contribute to the development of those hallmarks. Genomic instability provides a way that 
the tumor can gain new and probably more beneficial features to promote its growth. In 
particular, alterations in the genes involved in DNA repair enable an even higher 
accumulation of genomic instability. A cancer cell can harbor many different changes and 
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survive due to altered cell cycle regulators. (Hanahan and Weinberg, 2011) A tumor may 
be very heterogenic and consist of populations of genetically very different cells (de Bruin 
et al., 2014; Gerlinger et al., 2014). In addition to intra-tumor heterogeneity, metastases 
deriving from the primary tumor may be genetically different, and one metastasis can harbor 
different cell populations. Moreover, tumors between individuals are distinct. In other 
words, each cancer is unique displaying intra-tumor, inter-metastatic, intra-metastatic and 
inter-patient differences (Gerlinger et al., 2014). 
Cancer predisposition is caused by both environmental and genetic factors. An 
individual may be exposed to different carcinogenic or mutagenic agents due to the 
environment in which he/she lives or the life-style, such as asbestos, air pollution, tobacco 
smoke, alcohol, unhealthy diet, too little physical activity, micro-organisms and exposure 
to sunlight. Furthermore, an individual’s own genetic background plays a role, i.e this can 
either increase or decrease the risk for suffering cancer. (reviewed in Vineis and Wild, 2014) 
In conclusion, cancer development is a multifactorial and complex process, but altered 
genetics is always at its core (Hanahan and Weinberg, 2011). 
 
 
There are approximately 3 billion base pairs (bp) in the human genome. Although the 
sequence of the bases is a characteristic of humans, there are also often variations, such as 
single nucleotide polymorphisms (SNP). The DNA sequence can be altered once the cell 
undergoes cell division, i.e. mitosis, when the DNA structure is opened and undergoes 
replication. Small DNA changes include substitutions, small deletions and insertions, i.e. 
indels (Figure 1). 
The smallest DNA alteration is the single nucleotide variation (SNV); this is a point 
mutation, where one nucleotide has become altered. In a substitution, one nucleotide base 
is substituted by another: in a transition, a purine nucleotide changes to another purine 
(A/G), and in a transversion, a purine changes to a pyrimidine (C/T). If mutations occur in 
an exon, they may alter the translation of the protein’s amino acids. The mutation may be: 
1) synonymous, silent mutation, if the amino acid remains the same, 2) nonsense mutation, 
if the mutation leads to a stop codon in the middle of the sequence, and protein translation 
is stopped prematurely causing a truncated protein product, or 3) missense mutation, if an 
amino acid is replaced by some other amino acid. Nonsense and missense mutations are also 
known as non-synonymous mutations, and they may lead to the synthesis of a defective 
protein. 
DNA is transcribed in triplets of the nucleotides, i.e. codons, starting with a certain 
starting codon and ending with particular stop codons. Indels may cause a change in this 
reading frame and this can lead to an alteration called a frameshift mutation, or cause in-
frame insertion/deletion of codons. Moreover, indels can alter splice sites, i.e. DNA 







Genetic alterations may also include larger genomic changes. In many solid tumors, such as 
lung cancer, chromosomal changes are commonly present. These consist of deletions, 
duplications, inversions, substitutions, translocations (Figure 1) and changes in the 
chromosome number, i.e. aneuploidy (Vogelstein et al., 2013). The genome has also some 
particularly fragile sites that are prone to harbor translocations and deletions (reviewed in 
Durkin and Glover, 2007). 
Deletions cause a loss of genetic material, they may even delete the whole gene(s). 
Duplications lead to copy number variations (CNVs), where the copy number of genes is 
elevated, and thus the encoded protein becomes overexpressed. In the normal cell, there are 
two copies of every gene, one allele in each homologous chromosome. Inversions, 
substitutions and translocations rearrange genetic material. Those may produce fused genes 
with oncogenic features or inactivate genes by truncating those or removing them so they 
are no longer regulated by their promoters. If a loss or a gain of genetic material occurs, the 





Epigenetic changes are genetic alterations that do not alter the DNA sequence, but alter gene 
expression by other means. Examples of epigenetic changes are DNA methylation, histone 
protein modifications and expression of non-coding RNAs (nc-RNAs). The presence of 
epigenetic variability may account for the distinctly different risk for malignancies between 
individuals. Moreover, epigenetic alterations seem to be therapeutically important, and 
compounds inhibiting the activity of the enzymes regulating epigenetic events have been 
developed (reviewed in Morera et al., 2016). 
DNA methylation regulates gene expression in the genome. It occurs at genomic regions 
enriched with cytosine and guanine bps, called CpG islands. DNA methyltransferases 
(DNMTs) are enzymes that add methyl groups covalently to the cytosine bases. In 
hypermethylation, the methyl groups are added to DNA causing the silencing of DNA 
sequence. Hypermethylation in promoter sequences suppresses the gene expression. 
Hypomethylation is the opposite event, where the methyl groups are removed from the 
cytosines, thus promoting the gene expression. DNA methylation is an important regulator 
of normal development since this requires a strict time and tissue-specific regulation of gene 
expression. DNA methylation is a mechanism involved in X chromosome inactivation that 
is needed for normal development of females, who have two X chromosomes (reviewed in 
Goldberg et al., 2007). 
In cancer, methylation takes place commonly in the promoter regions of specific tumor 
suppressor genes, leading to their inactivation. Hypermethylation is commonly seen in the 
genes that harbor also somatic mutations, and are essential for the cell function, such as 
DNA repair, cell cycle control, motility and proliferation. However, hypomethylation also 
can be encountered in malignant tumors although it occurs less specifically and more likely 
at later stages of tumorigenesis. Hypomethylation may cause an activation of oncogenes and 
loss of imprinting. (reviewed in Langevin et al, 2015) 
CpG islands are frequently mutated. For instance, the CpG island in the TP53 gene 
harbor approximately 50 % of all somatic mutations in this gene (Rideout et al., 1990). 
Methylation may also increase carcinogenic effects, as has been shown in a case of some of 
the carcinogens present in tobacco smoke - acrolein (Feng et al., 2006) and benzo(a)pyrene 
diol epoxide (BPDE) (Yoon et al., 2001). If there is deamination, i.e. removal of an amine 
group, of methylcytosine, this can make this methylated base susceptible to a C>T transition 
point mutations, and transversion (G>T) mutations by promoting the effect of exogenous 
carcinogens (Langevin et al., 2015). 
Histones are proteins involved in packing of genomic DNA into the chromatin structure. 
The basic structure of chromatin is called a nucleosome; this is formed by two of each 
histone types (H2A, H2B, H3 and H4), around which DNA is wrapped. Histones have N-
terminal tails, which are available for post-transcriptional modifications. There are specific 
enzymes to catalyze these modifications e.g. methylation, acetylation, deamination, 
ubiquitylation, phosphorylation and sumoylation (Goldberg et al., 2014). These 
modifications alter the histones and, depending on the site of modifications, may further 
affect the chromatin structure and gene expression (Langevin et al., 2015). Histone 
modifications, and alterations in other proteins involved in those modifications, are clearly 
associated with the development of malignancy. For instance, deacetylation, i.e. removal of 
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an acetyl group from the histone tail leads to transcriptionally inactive DNA (Langevin et 
al., 2015). 
Non-coding RNAs (ncRNAs) are a group of RNA sequences that are transcribed from 
the genes but are not translated into proteins. They can be divided into groups based on their 
size, from short to long ncRNAs. The most widely studied group is a type of short non-
coding RNAs (sncRNAs) called microRNAs (miRNA) that are of ~18–22 nucleotides in 
length. They inhibit gene expression in a sequence-specific manner by binding to the 
complementary messenger-RNA (mRNA) molecule transcribed from the target gene 
(reviewed in Langevin et al., 2015, and Tuna et al., 2016). Dysregulation of miRNAs leads 
to altered expression of their target genes for example, in cancer, they may promote 
upregulation of oncogenes and inhibit tumor suppressors. The deregulation of miRNAs can 
be induced by mutations, deletions, copy number alterations, amplifications and epigenetic 
alterations (Tuna et al., 2016). Long non-coding RNAs (lncRNAs) (> 200 nucleotides) are 
also able to regulate gene expression, and possibly they are also involved in protein 
regulation and structural organization (reviewed in Shi et al., 2013, and Schmitt and Chang, 
2016). 
From therapeutic point of view, miRNAs are intriguing targets, and promising results 
have been obtained when they have been evaluated in cancer models. Inhibition of specific 
miRNAs has been found to repress oncogenic miRNAs, but to date, none of the therapeutic 
agents have been approved for clinical use. Further research will be required before this goal 
is achieved, especially to overcome delivery challenges and to decrease unwanted effects. 




Lung cancer is the most incident type of cancer and a major cause of global cancer-related 
deaths, being responsible for up to 1.8 million newly diagnosed cases and 1.6 million deaths 
annually (Ferlay et al., 2015). This value represents 13 % of all new cancer cases and 19 % 
of all cancer-related deaths. Every year in Finland, there are approximately 2 500 new cases 
of lung cancer are diagnosed, two out of every three in male patients, and approximately 2 
100 lung cancer-related deaths (Engholm et al., 2015). This means that lung cancer causes 
11 % and 24 % in males, and 6 % and 12 % in females of all cancer cases and cancer-related 
deaths, respectively. In Finland, prostate cancer in male and breast cancer in female remain 
the most common cancer types (Engholm et al., 2015). The vast majority of lung cancers 
are diagnosed in patients older than 55 years of age (reviewed in de Groot and Munden, 
2012). 
Although cancer mortality rates have decreased in all those countries with reliable data, 
lung cancer remains very lethal (Hashim et al., 2016). The mortality rates are rising, 
particularly among female patients (Hashim et al., 2016) reflecting the increase in tobacco 
smoking incidence in women (de Groot and Munden, 2012). Tobacco smoke is the major 
cause of lung cancer, and specific subgroups of small cell carcinoma and squamous cell 
carcinoma are linked to cigarette consumption. In contrast, adenocarcinoma is the most 
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common subgroup in never-smoker patients, especially in women (reviewed in de Groot 
and Munden, 2012, and IARC, 2012a). It has been estimated that up to 85–90 % of all lung 
cancer cases are caused by tobacco smoke; however, only approximately 15 % of all 
smokers develop lung cancer (reviewed in  de Groot and Munden, 2012, and Pallis et al., 
2013). Tobacco smoke includes more than 70 known carcinogens that lead to the formation 
of DNA adducts and mutations (IARC, 2012a). Cessation of smoking lowers the risk for 
lung cancer (de Groot and Munden, 2012; IARC, 2012a), although the risk does not decrease 
to the level it was before the individual started to smoke (reviewed in Karam-Hage et al, 
2014). Smoking not only elevates risk for lung cancer, but its component, nicotine, might 
also alter the resistance of the tumors towards radio- and/or chemotherapy (reviewed in 
Warren et al., 2013). Additionally, asbestos fibers, radon, micro-organisms, air pollution, 
such as polycyclic hydrocarbon (PAH) compounds, wood dust (Hancock et al., 2015) and 
genetic susceptibility have been linked to an increased risk for developing lung cancer (de 
Groot and Munden, 2012; Pallis et al., 2013). 
 
 
Lung cancer is diagnosed commonly only during the late stages of the disease. The diagnosis 
is based on clinical symptoms and lung imaging by radiography and/or computed 
tomography (CT) (reviewed in Ettinger et al., 2010, and Lemjabbar-Alaoui et al., 2015). A 
more detailed pathological and molecular diagnosis is made from resected sample or small 
biopsies obtained during surgical or diagnostic procedures (Ettinger et al., 2010). Tumors 
are staged at diagnosis by according to the tumor, node and metastasis (Union for 
International Cancer Control (UICC) TNM) classification which defines the size of primary 
tumor (T), cancer cell spread into the adjacent lymph nodes (N) and distant metastases (M) 
(Sobin et al., 2009). According to the latest edition, the stages are defined as Ia, Ib, IIa, IIb, 
IIIa, IIIb and IV. Stages Ia–IIIb represent local and locally advanced cancer (spread to 
lymph nodes), whereas stage IV describes cancer metastatic to other organs (Sobin et al., 
2009; Lemjabbar-Alaoui et al., 2015). Staging is important as a prognosticator of the 
patient’s outcome and it represents the basis for evaluating and planning the treatment 
(reviewed in Lemjabbar-Alaoui et al., 2015, and Tsao et al., 2016). 
Although all lung cancers share the same origin, it is important to subgroup them 
correctly, as subgroups represent clinically different diseases (Travis et al., 2015). Lung 
cancer can be divided into two major groups based on their histopathological features: non-
small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most 
common group accounting for to 85 % of all cases; its origin is in the lung epithelium, 
whereas SCLC derives from the hormonal neuroendocrine cells (Lemjabbar-Alaoui et al., 
2015). SCLCs are undifferentiated and very aggressive cancers, which commonly spread 
into lymphatic vessels and lymph nodes and also to the brain (Lemjabbar-Alaoui et al., 
2015). This thesis focused on NSCLCs. NSCLCs are a heterogeneous group of lung tumors 
and they can be divided further into smaller subgroups based on their characteristic 
histopathology (Lemjabbar-Alaoui et al., 2015; Travis et al., 2015). The largest subgroups 
of the NSCLCs are adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell 
carcinoma (LCC) (Ettinger et al., 2010). Tumors of distinct subgroups may emerge through 
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molecularly different tumorigenesis pathways (reviewed in Kadara et al., 2016), and derive 
from pulmonary different sites: ADC is found in the peripheral sites, whereas SCC in 
centrally located in the major bronchi. LCC tends to be poorly differentiated and can be 
found in any parts of the lung (Lemjabbar-Alaoui et al., 2015). 
NSCLCs are very complex tumors and the subgrouping needs to be done in great detail 
(Lemjabbar-Alaoui et al., 2015; Kadara et al., 2016). In 2015, the new 4th edition of World 
Health Organization (WHO) classification was published for lung tumors, the previous 
version dating from 2004 (Travis et al., 2015). The major changes included a 
recommendation to use immunohistochemistry (IHC) in addition to morphological features 
also for resected tumor samples. IHC markers can be used to distinguish tumors if the 
morphology is unclear, as it may well be the case with small biopsies and cytological 
samples. There are five IHC markers that are approved for use in the classification of 
NSCLCs, i.e. thyroid transcription factor 1 (TTF-1) and napsin-A, both with a sensitivity of 
80 %, for ADCs; and P40, which is the most sensitive and specific, followed by P63 and 
cytokeratin 5/6 (CK5/6) for SCCs (Travis et al., 2015). The second major change was to 
include genetic testing in the diagnosis as a way of selecting some form of targeted therapy. 
Moreover, it was recommended that the group of LCC should include only undifferentiated 
tumors (lack of any morphological and IHC differentiation), others should be in different 
subgroups. A new classification for ADC as defined by the International Association for the 
Study of Lung Cancer/American Thoracic Society/European Respiratory Society 
classification (IASLC/ATS/ERS) of 2011 was also largely included. The revised version is 
based on tumor cell invasiveness: ADC in situ (AIS), minimally invasive (MIA) and 
invasive; and growth pattern: solid, lepidic, acinar, papillary and micropapillary 
predominances (Travis et al., 2011). However, due to the timing of this study, the 3rd edition 
of WHO classification from 2004 has been used in this thesis (Travis et al., 2004). 
The correct classification is very important from a prognostic and therapeutic point of 
view, as further molecular testing and therapeutic options are based on the classification 
(Travis et al., 2015). For instance, patients with SCC show no or only a poor response to 
pemetrexed (Scagliotti et al., 2011), and bevacizumab is highly toxic since there is a high 
risk that it will cause severe pulmonary bleeding in SCC patients (Johnson et al., 2004). 
Moreover, resected ADC with micropapillary or solid predominance display an increased 
response to adjuvant chemotherapy compared to acinar or papillary predominant tumors 
(Tsao et al., 2016). Some molecular changes reflecting the sensitivity for targeted therapies, 
such as EGFR mutations and ALK fusions, are mostly found in ADCs and thus it is 
recommended that tumors with an ADC classification, and those in which ADC cannot be 
excluded, should be molecularly tested (Travis et al., 2015; Tsao et al., 2016). 
 
 
Lung cancer cells harbor defects in their regulatory systems. Transformation into a 
malignant cell is thought to occur in a multistep and sequence-specific process driven by 
the accumulation of genetic and epigenetic changes (Lemjabbar-Alaoui et al., 2015; Kadara 
et al., 2016). Lung tumors vary extensively in their genetics, and thus there are no identical 
tumors. Moreover, the tumors are heterogenic and consist of various subclones of malignant 
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cells harboring somatic mutations and many other alterations (de Bruin et al., 2014). For 
these reasons, it is very difficult to identify the most significant changes and those with 
driver capabilities (Vogelstein et al., 2013). 
In recent years, major efforts have been expended in conducting comprehensive genetic 
screening studies. Some specific genetic alterations occur more often in ADCs, and on the 
other hand, others in SCCs (Cancer Genome Atlas Research Network 2012 and 2014; 
reviewed in Devarakondra et al., 2015). In ADCs, RTK/RAS/RAF pathway activation (76 
%), PI3K-mTOR pathway activation (25 %), p53 pathway alteration (63 %), alterations of 
cell cycle regulators (64 %), alterations of oxidative stress pathways (22 %), and mutations 
of various chromatin and RNA splicing factors (49 %) are common (proportions of all 
cases). In a whole exome sequencing study of ADCs, eighteen genes were found to harbor 
at a significant rate somatic alterations of non-synonymous mutations, rearrangements or 
CNVs (Cancer Genome Atlas Research Network 2014). These significantly mutated genes 
included (proto-)oncogenes (EGFR, KRAS, BRAF, MET, PIK3CA), tumor suppressors 
(TP53, STK11, KEAP1, NF1, RB1, CDKN2A), chromatin modifying (SETD2, ARID1A, 
SMARCA4), RNA splicing (RBM10, U2AF1), transcription factor (MGA), GTPase (RIT1) 
genes. The somatic mutations were detected with a frequency of 8.87 mutations per mega 
base of DNA. The significant somatic amplifications were detected in the following genes: 
NKX2-1, TERT, MDM2, KRAS, EGFR, MET, CCNE1, CCND1, TERC, MECOM, in 
chromosomal region of 8q24 near MYC, and a novel peak containing CCND3, and deletions 
in CDKN2A. Moreover, hypermethylation was clearly observed in genes involved in the 
WNT pathway (Cancer Genome Atlas Research Network 2014). In a RNA-sequencing 
study, fusions were found to be present with the ROS1, RET, PRKCB, NTRK, MET and ALK 
genes (Stransky et al., 2014). 
Similarly, pathways of NFE2L2/KEAP1 (34 %), squamous differentiation genes 
(SOX2/p63/NOTCH1) (44 %), PI3K/AKT (47 %), and CDKN2A/RB1 (72 %) have been 
found to be significantly altered in SCCs (proportions of all cases) (Cancer Genome Atlas 
Research Network 2012). The tumor suppressor gene CDKN2A was silenced by distinct 
mechanisms of methylation, mutation, exon skipping and deletion in 72 % of SCCs.  
Significantly mutated genes were: TP53, CDKN2A, PTEN, PIK3CA, KEAP1, MLL2, HLA-
A, NFE2L2, NOTCH1 and RB1, when considering all genes, plus FAM123B, HRAS, 
FBWX7, SMARCA4, NF1, SMAD4, EGFR, APC, TSC1, BRAF, TNFAIP3 and CREBBP, 
when considering only genes annotated in the Catalogue of Somatic Mutations in Cancer 
(COSMIC). Those included (proto-)oncogenes (PIK3CA, EGFR, BRAF, HRAS), other 
membrane receptor (NOTCH1), tumor suppressors (TP53, CDKN2A, PTEN, KEAP1, RB1, 
APC, TSC1), chromatin modifying (MLL2, SMARCA, CREBBP), pathway regulators 
(FAM123B, NF1, SMAD4), ubiquitination (FBWX7), transcription factor in oxidative stress 
(NFE2L2), and immune system related (HLA-A, TNFAIP3) genes. Tumors were also 
characterized by a chromosomal 3q gain. The observed mutation frequency was 8.1 
mutations per mega base of DNA (Cancer Genome Atlas Research Network 2012). In 
another study, fusions were detected in PRKCB, PRKCA, PKN1, FGR, FGFR1, FGFR2 and 
FGFR3 in SCC (Stransky et al., 2014). 
Nowadays, the information of molecular changes of ADCs is being applied in the clinic 
(Travis et al., 2015). EGFR mutations and ALK fusions are studied, and specific inhibitors 
are administered to treat the patients with these particular alterations (reviewed in 
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Thunnissen et al., 2014, and Patel et al., 2015). Moreover, numerous studies are ongoing to 
find predictive molecular markers, and to develop new therapeutic agents to treat 
molecularly different tumors. Table 1 lists some of most common genetic changes and novel 





Epidermal growth factor receptor (EGFR) gene is located on chromosome 7q12. It encodes 
a transmembrane protein, EGFR, which belongs to ERBB family of the receptor tyrosine 
kinases (RTKs) (GeneCards). Like the other RTKs, EGFR is a cell surface receptor; it is 
activated by ligand binding which triggers the dimerization of the receptor molecules 
inducing autophosphorylation of its tyrosine amino acids in the kinase domain, which leads 
to the activation of downstream signaling pathways, RAS/RAF/MEK and 
PI3K/AKT/mTOR, regulating the cell proliferation, differentiation and apoptosis (Sordella 
et al., 2004). 
EGFR mutations occurring in the intracellular protein kinase domain (exons 18–21) can 
cause the constitutive activation of the receptor molecule and thus activation of the whole 
downstream signaling pathway even without ligand binding (Figure 2). These mutations 
alter the ATP-binding pocket of the receptor, which makes possible its activation without 
ATP binding. There are two common activating mutations, a single bp substitution causing 
a change in amino acid in the protein from leucine to arginine at codon 858 (Leu858Arg) in 
exon 21, and deletions in exon 19. Other activating mutations with known clinical 
significance are insertions in exon 20 and various missense mutations, such as Ser768Ile, 
Gly719Ala/Ser/Cys, Thr790Met and Leu861Gln. (reviewed in Sharma et al., 2007) EGFR 
mutations are reported to be largely mutually exclusive with other driver alterations, such 
as KRAS, BRAF mutations and ALK fusions (Dearden et al., 2013; Gainor et al., 2013; 






EGFR mutations are found with a frequency of close to 10 % in European NSCLC patients 
(Gahr et al., 2013). In Asian NSCLC patients, the incidence is higher - as high as 50 % 
(Dearden et al., 2013). EGFR mutations are associated with ADC histology, female gender, 
never-smoking status and Asian ethnicity (Dearden et al., 2013). Certain activating EGFR 
mutations predict that the patient will respond favorably to small molecule receptor tyrosine 
kinase inhibitors (TKI), such as gefitinib, erlotinib and afatinib (Figure 2) (Mok et al., 2009; 
Zhou et al., 2011; Sequist et al., 2013). However, some of the mutations predict insensitivity 
to targeted drugs, and acquired mutations can cause resistance to targeted treatments after a 
good initial response (Sequist et al., 2011a and 2011b). 
 
 
Anaplastic lymphoma kinase (ALK) gene is located on chromosome 2p23 encoding the ALK 
receptor, which also belongs to the RTK family (GeneCards). Normally, the ALK receptor 
has an important role in the development of the brain, but alterations in this gene are found 
in cancer causing the downstream activation of RAS/MEK/ERK, STAT3 and PI3K/AKT 
pathways regulating cell proliferation, differentiation, survival and apoptosis (reviewed in 
Shaw and Solomon, 2011). 
In lung cancer, ALK is activated by a translocation leading to constitutive dimerization 
of the receptor and induction of cell proliferation and survival via altered signaling 
pathways. Several fusion partners have been detected, such as KIF5B, TFG and KLC1, but 
the most common is a small inversion in the chromosome arm 2p, causing ALK to fuse with 
EML4 (Figure 3). This ALK-EML4 fusion occurs in exon 20 of ALK and it includes its 
tyrosine kinase domain, but EML4 is truncated at distinct locations. (Soda et al., 2007; 
Takeuchi et al., 2009) 
ALK fusions can be detected in approximately 3 % of unselected NSCLC patients. They 
are associated with ADC histology, never- or light smoking status and younger age, and are 
mutually exclusive with other driver mutations. The ALK-EML4 fusion predicts sensitivity 
towards ALK inhibitors, such as crizotinib and ceritinib. (Shaw et al., 2009; Sequist et al., 






Erythropoietin-producing human hepatocellular receptor-interacting protein (ephrin) 
receptors (Ephs) form the largest group of RTKs. At present, gene family encoding the 
receptors has 14 members: EPHA1-8, EPHA10, EPHB1-4 and EPHB6. Their ligands are 
ephrins, five in class A and three ephrin-B ligands. Some of the receptors have more than 
one ligand. Ephs differ in their signaling from other RTKs. Both a receptor molecule and a 
ligand are located on the cell surface, which leads to a contact-dependent cell interaction 
and bidirectional signaling. Forward signaling is dependent on Eph kinase activity, and 
reverse signaling on Src kinases. Moreover, the same cell can express both receptors and 
ligands, and even inhibit the signal induced by Ephs. In addition, some Ephs can act 
independently from ephrins. The crosstalk between different members of the large Ephs 
family and with other signaling pathway mediators, means that Ephs are crucial actors in 
cell signaling. The ephrin-mediated signaling is involved in various developmental events 
and cell homeostasis by regulating cell morphology, adhesion, proliferation, migration, 
survival and differentiation. The signaling outcome is highly dependent on cells and tissues. 
(reviewed in Pasquale, 2010, and Lisabeth et al., 2013) 
Aberrations in Ephs and ephrins have been found in many cancers, and they have 
displayed both tumor suppressive and tumorigenic potential (Lisabeth et al., 2013). Ephs 
can promote signaling via Rho and Ras family GTPases in various pathways (Lisabeth et 
al., 2013). Intriguingly, Ephs can utilize those GTPases to suppress cell proliferation, 
survival and migration, this differs from the situation with the other RTKs using the same 
downstream signaling mediators (Pasquale, 2010; Lisabeth et al., 2013). Eph signaling 
promotes epithelial phenotype, and suppresses cell adhesion, migration and growth 
(Pasquale, 2010). In lung cancer, mutations have been found particularly in EPHA3 and 
EPHA5 (Davies et al., 2005; Ding et al., 2008) as well as alterations in the expressions of 
multiple Ephs (reviewed in Barquilla and Pasquale, 2015). They might also possess a 
prognostic role, such as high expression of EPHA8 in ovarian cancer (Liu et al., 2016a), and 
EPHB2 (Husa et al., 2016) in breast cancer predict poor survival. In addition, EPHA2 
expression has been associated with a poor prognosis in many cancers, except lung cancer, 
as revealed in a recent meta-analysis (Shen et al., 2014). Germline CNVs of EPHA3 have 
been linked to susceptibility to hereditary prostate cancer in Finland (Laitinen et al., 2016). 
Since they are such a diverse group of RTKs, Ephs are an intriguing group from the 
therapeutic point of view, and multiple agents inhibiting or promoting Ephs are under the 
investigation (Barquilla and Pasquale, 2015). For instance, an EPHA2 inhibitor has shown 
good results in NSCLC cell lines in a preclinical study (Amato et al., 2014). NSCLC cells 
with increased CNV in EPHA3, EPHA5 and EPHA8 exhibited sensitivity to dasatinib, a 
wide-range kinase inhibitor (Sos et al., 2009). Aberrations in Ephs may also alter therapy 
outcome. Increased expression of EPHA2 can lead to resistance to trastuzumab in breast 
cancer (Zhuang et al, 2010) and vemurafenib in melanoma (Miao et al., 2015); EPHB3 has 
been demonstrated to promote resistance to radiotherapy in NSCLC cells (Ståhl et al., 2013); 
and polymorphisms in EPHA5 and EPHA6 are thought to play a role in chemotherapy 
(taxanes) toxicity in solid tumors (reviewed in Frederiks et al., 2015). Moreover, Ephs have 
been shown to participate in cancer-related epithelial-mesenchymal transition (EMT) (Li et 
al., 2014a), which is a mechanism allowing tumors to resist targeted therapies (reviewed 
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Uramoto et al., 2010; Chung et al., 2011). In summary, this makes Ephs a very interesting 
group of molecules. 
 
 
In addition to the somatic changes in DNA, epigenetic alterations are very frequently 
encountered in lung cancer. Lung tumors express similar hypermethylated tumor suppressor 
genes as observed in other solid tumors (Langevin et al., 2015). There are many 
hypermethylated genes e.g. tumor suppressors of RASSF1A, APC and CDKN2A, and DNA 
repair gene MGMT. Multiple repetitive sequences, such as short and long interspersed 
nuclear elements (SINE and LINE), long transposable repeat (LTR) elements, duplicates 
and subtelomeric sequences, are frequently hypomethylated in SCC, as is commonly the 
case in other human cancers (Rauch et al., 2008). The methylation pattern seems to change 
in the course of tumorigenesis (Langevin et al., 2015). 
There are also histone modification-related epigenetic changes in lung cancer; the 
HDACs are overexpressed, and a SIN3A involved in suppression of HDAC is 
downregulated, leading to closed chromatin assembly and subsequently suppression of gene 
expression, particularly of tumor suppressors (Langevin et al., 2015). Moreover, 
hyperacetylation of H4K5 and H4K8, hypoacetylation of H4K12 and H4K16, and loss of 
trimethylation of H4K20 have been detected in lung cancer (van den Broeck et al., 2008; 
Langevin et al., 2015). 
NcRNAs are also altered in lung cancer, for instance, miR-21 and miR-210 seem to be 
more overexpressed than in normal lung, as shown in multiple studies (Guan et al., 2012; 
Võsa et al., 2013). MiR-21 inhibits gene expression of PTEN, PDC4 and TPM1, promoting 
angiogenesis and tumor growth in hepatocellular carcinoma (Meng et al., 2007). There are 
several miRNAs which have been reported to be methylated and thus inactivated (Langevin 
et al., 2015). The hypomethylation of one miRNA, let-7a-3, leads to the dysregulation of 
more than 200 genes, among those (proto-)oncogenes RAS, MYC and HMGA2, and thus can 
promote tumorigenesis (Brueckner et al., 2007). With respect to the lncRNA genes, 
MALAT1 and HOTAIR are overexpressed, the former is thought to inhibit genes regulating 
metastasis and cell motility, while the latter is involved in regulating the histone regulatory 
complexes; both of these NcRNAs have highly conserved RNA sequences in mammals 
(Langevin et al., 2015). 
Epigenetic alterations may also be relevant for therapeutics. Two inhibitors against the 
enzymes regulating epigenetic events have been tested in lung cancer i.e. DNMT and HDAC 
inhibitors (Langevin et al., 2015). However, at present they are not approved for treatment 
of lung cancer. Four HDAC inhibitors have been approved by the Food and Drug 





Lung tumors are largely treated with the standard methods: surgery, radio- and 
chemotherapy. If a tumor is found in its early stages, surgery is the most curative treatment 
option. The resection of lung tumors are large operations and cannot be conducted on 
patients in a very weak condition. More advanced NSCLCs are treated with a combination 
of radio- and platinum-based chemotherapies. Surgery can also be combined with radio- 
and chemotherapy. Neo-adjuvant therapy is given before the surgical operation to decrease 
the size of the tumor, and adjuvant therapy after the operation to destroy left-over malignant 
cells. (Lemjabbar-Alaoui et al., 2015; Tsao et al., 2016) 
Lung tumors are most commonly treated with the standard methods: surgery, radio- and 
chemotherapy, or their combinations. If a tumor is detected while in its early stages, surgery 
is still the most appropriate treatment option, despite the emergence of “radio-surgery” with 
focused high-dose stereotactic radiotherapy. Resection of lung tumors is a major surgical 
procedure which cannot be performed on patients with comorbidities, as is often the case. 
In these cases, radiotherapy may be a better option. More advanced NSCLCs are treated 
with a combination of radio- and platinum-based chemotherapies. Neo-adjuvant therapy is 
given before the surgical operation to decrease the size of tumor, and adjuvant therapy after 
the operation to destroy any left-over malignant cells. In neo-adjuvant and adjuvant 
situations mainly radiotherapy and chemotherapy modalities are used. (Lemjabbar-Alaoui 
et al., 2015; Tsao et al., 2016) 
 
 
Targeted treatments have been developed; these are aimed at certain aberrant proteins or 
molecules in the cell driving the tumorigenesis (Thunnissen et al., 2014). The target should 
be measurable by a predictive biomarker that should monitor the clinical outcome after the 
applied treatment (Patel et al., 2015). At present, ALK and EGFR targeted therapies are 
approved to treat NSCLC patients with ALK fusion and activating EGFR mutations, 
respectively (Travis et al., 2015; Abramson, 2016). Those therapies improve the outcome 
of the patients harboring the alterations, compared to standard chemotherapy (Patel et al., 
2015). For patients whose tumors harbor activating EGFR mutations, EGFR-TKI therapy 
(erlotinib, gefitinib or afatinib) is recommended (Lemjabbar-Alaoui et al., 2015; Travis et 
al., 2015). Those small molecule inhibitors inhibit EGFR signaling and induce apoptosis in 
cancer cells. Recently, immunotherapy (nivolumab) has been approved by FDA as 
treatment of advanced SCCs (Travis et al., 2015; Abramson, 2016). 
However, regardless of all the success in the investigation of biomarkers and targeted 
treatments, only a fraction of patients with NSCLC can benefit from those therapies. Thus, 
SCCs and a majority of ADCs are still treated with the standard methods (Lemjabbar-Alaoui 
et al., 2015). In the future, identification of novel targetable alterations and new drugs, as 





EGFR inhibitors consist of monoclonal antibodies (mAb) and small molecule inhibitors. 
The antibodies downregulate EGFR and subsequently inhibit its downstream signaling by 
competitively preventing the binding of ligand to the binding site of the receptor (reviewed 
in Pirker, 2015). These drugs are beneficial for NSCLC patients with high levels of EGFR 
expression in their tumors. Phase III randomized clinical trials have demonstrated the 
efficacy of the first generation antibody, cetuximab, and the second generation drug, 
necitumumab (Pirker, 2015). A meta-analysis claimed that cetuximab plus platinum-based 
chemotherapy could increase overall survival (OS) in advanced NSCLC patients compared 
to chemotherapy alone i.e. 10.3 months vs. 9.4 months (HR=0.88; 95 % CI, 0.79–0.97; 
p=0.009) (Pujol et al., 2014). Similarly, patients receiving necitumumab plus gemcitabine 
and cisplatin showed longer a OS of 11.5 months compared to 9.9 months for gemcitabine 
and cisplatin (HR=0.84; 95 % CI, 0.74–0.96; p=0.01) in advanced SCCs (Thatcher et al., 
2015). 
EGFR-TKIs are reversible or irreversible drugs, binding competitively to intracellular 
ATP-binding pocket of the tyrosine kinase domain of EGFR. TKI prevents ATP-binding 
and subsequently phosphorylation of EGFR, leading to downregulation of survival and 
proliferation signaling pathways (Sharma et al., 2007). In 2003, gefitinib was approved by 
FDA for previously treated advanced NSCLC (Cohen et al., 2003), and a year later, 2004, 
erlotinib received a similar approval (Cohen et al., 2005). In 2004, the first studies 
describing the association between the EGFR mutations and the efficacy of EGFR-TKIs 
were published: EGFR mutation positive NSCLC patients showed a clear sensitivity 
towards two first-generation EGFR-TKIs i.e. gefitinib (Lynch et al., 2004; Paez et al., 2004; 
Pao et al., 2004) and erlotinib (Pao et al., 2004). At present, both gefitinib and erlotinib are 
approved as first-line monotherapy for advanced (or metastatic) EGFR-mutation positive 
NSCLCs (Lemjabbar-Alaoui et al., 2015; Abramson, 2016). Moreover, second and even 
third generation EGFR-TKIs are available and approved as targeted therapy for advanced 
NSCLCs. Whereas the first generation drugs bind reversibly, the second generation drug, 
afatinib, forms irreversible covalent bonds with EGFR. Afatinib was developed to target a 
resistance-causing gatekeeper mutation, Thr790Met, but it did not overcome the resistance 
(reviewed in Minguet et al., 2016). The third-generation drugs, of which osimertinib is 
approved by FDA, are similarly irreversible and target also the gatekeeper mutation in 
addition to the activating EGFR mutations, while not binding to wild-type EGFR, which 
decreases their toxicity (reviewed in Tan et al., 2016). 
In phase III randomized controlled trials, Mitsudomi et al. (2010) reported longer median 
progression free survival (PFS) for gefitinib-treated patients compared to cisplatin plus 
docetaxel treated: 9.2 months vs. 6.3 months (HR=0.49; 95 % CI, 0.34–0.71; p>0.0001). 
Similarly, PFS of 13.1 months for erlotinib compared to 4.6 months for gemcitabine plus 
carboplatin (HR=0.16; 95% CI, 0.10–0.26; p>0.0001) (Zhou et al., 2011), and 11.1 months 
for afatinib compared to 6.9 months for cisplatin plus pemetrexed (HR=0.58; 95 % CI, 0.43–
0.78; p=0.001) have been reported (Sequist et al., 2013). Moreover, afatinib showed benefit 
in PFS over erlotinib as a second-line treatment for advanced SCC: 2.6 months vs. 1.9 
months (HR=0.81; 95 % CI, 0.69–0.96; p=0.0103) (Soria et al., 2015). Furthermore, an 
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increase in OS over erlotinib was reported: 7.9 months vs. 6.8 months (HR=0.81; 95 % CI, 
0.69–0.95; p=0.0077) (Soria et al., 2015). 
Osimertinib has shown good results in phase I/II clinical trials and is now undergoing a 
phase III trial. It is also under investigation for combination with other (novel) therapeutic 
agents (reviewed in Pirker et al., 2016, and Wang et al., 2016). In a phase I trial, the median 
PFS for osimertinib treated T790M positive advanced NSCLC patients was 9.6 months (95 
% CI, 8.3 – not reached) vs. 2.8 months (95 % CI, 2.1–4.3) in T790M negative patients 
(Jänne et al., 2015). Other third generation drugs, such as rociletinib, are also under further 
investigation, having shown promising results in advanced NSCLC with T790M mutations 
(Minguet et al., 2016). 
Taken together, a recent meta-analysis which assessed 30 randomized controlled trials, 
showed EGFR mutation positive patients treated with EGFR-TKIs enjoyed a clear PFS 
benefit over chemotherapy or placebo treatment, both in first-line and second/third-line 
settings (Liu et al., 2016b). Lee’s et al. (2015) meta-analysis produced similar results, 
achieving the greatest benefit in female, never-smokers and exon 19 deletions EGFR 
positive patients. Moreover, patients with exon 19 deletions were observed to have 
increased OS when treated with first-line irreversible EGFR-TKIs compared with those 
patients with exon 21 Leu858Arg (Kuan et al., 2015). It has been suggested that exon 19 
deletion positive patients form their own entity. Yang et al. (2015) analyzed OS data of 
EGFR-mutation positive ADCs comparing afatinib and cisplatin-based chemotherapy, and 
observed longer OS longer in patients with exon 19 deletion treated with afatinib compared 
to pemetrexed-cisplatin: 33.3 months vs. 21.1 months (HR=0.54; 95 % CI, 0.36–0.79; 
p=0.0015) and similarly compared to gemcitabine-cisplatin: 31.4 months vs. 18.4 months 
(HR=0.64; 95 % CI, 0.44–0.94; p=0.023). 
 
 
ALK inhibitors are also small molecule inhibitors that have displayed in PFS level efficacy 
in advanced ALK fusion positive NSCLC (Shaw and Engelman, 2013). At present, there 
are three FDA-approved ALK inhibitors available for clinical use: crizotinib, ceritinib and 
alectinib (Abramson, 2016), although only crizotinib is available in Finland. Ceritinib and 
alectinib have been claimed to function against brain metastases and gatekeeper mutations 
causing crizotinib-resistance, and are thus approved for treating metastatic, crizotinib-
resistant, ALK positive disease (Khozin et al., 2015). In 2011, crizotinib was approved for 
the second-line treatment of advanced ALK positive NSCLCs, and two years later as a first-
line treatment (Malik et al., 2014). 
In a randomized phase III trial, crizotinib was found to be superior over 
pemetrexed/docetaxel chemotherapy in ALK fusion positive advanced or metastatic 
NSCLC: PFS 7.7 months vs. 3.0 months (HR=0.49; 95 % CI, 0.37–0.64; p<0.001) (Shaw 
et al., 2013). Similarly, the superiority of crizotinib over chemotherapy was reported in the 
first-line treatment for ALK positive non-squamous NSCLCs (Solomon et al., 2014). In a 
phase I trial, ceritinib showed good responses in advanced NSCLCs with ALK fusion either 
with or without crizotinib-resistance mutations, and thus it may be able to overcome 
crizotinib resistance (Shaw et al., 2014). Alectinib was recently approved after displaying 
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good responses and tolerability in a phase II trial in ALK fusion positive crizotinib-resistant 
NSCLC patients (Shaw et al., 2016). Further clinical trials with ceritinib and alectinib are 
ongoing (Minguet et al., 2016). 
 
 
Inhibition of angiogenesis is a recognized anti-cancer treatment (Minguet et al. 2016). 
However, in lung cancer, the treatment effect has been rather disappointing. In randomized 
phase III trials, bevacizumab, an anti-VEGF-A, prolonged PFS in advanced non-squamous 
NSCLCs when used in combination with chemotherapy (cisplatin plus gemcitabine) up to 
only 6.7 months compared to 6.1 months with only chemotherapy, i.e. around 2.5 weeks 
(HR=0.75; 95 % 0.62–0.91; p=0.003) (Reck et al., 2009). Similar results in PFS were 
reported a year later (Reck et al., 2010). Although the difference may be statistically 
significant, there is no true clinical value. In addition, bevacizumab poses an increased risk 
of potentially fatal hemorrhage, making the drug not well-suitable for treatment of lung 
cancer (Johnson et al., 2004). Other inhibitors against angiogenesis signaling are under 
investigation, one of the most promising agents is nintedanib. It has been claimed to be 
beneficial for ADC patients when used in combination with chemotherapy in comparison 
with chemotherapy alone (Reck et al., 2014). 
 
 
Immunotherapy exploits the patient’s own immune system to attack cancer cells by 
targeting signaling pathways that are used by malignant cells to escape from immune 
recognition. Targeting immune checkpoint inhibitors in PD-1/PD-L1 (programmed death-1 
receptor/programmed death-1 ligand) pathway, or CTLA-4 (cytotoxic T-lymphocyte 
antigen 4) enables the immune system to recognize cancer cells and attack them (reviewed 
in Keir et al., 2008, and Farkona et al., 2016). Cancer cells express PD-L1 protein on their 
surfaces serving as a ligand for PD-1 receptor expressed on the surface of activated T-cells. 
The ligand-receptor interaction inactivates T-cells and inhibits the immune response (Keir 
et al., 2008). If one can block this interaction, T-cells may be activated and mount an 
immune attack against tumor cells (Keir et al., 2008). The immune checkpoint inhibitor, 
CTLA-4, is expressed on the surface of T-cells and after binding of its ligands, CD80 and 
CD86, it inhibits T-cell activity. By blocking CTLA-4, the immune response can be 
activated against tumor cells (Farkona et al., 2016). 
In 2015, nivolumab, a PDL-antibody, was approved by FDA for the treatment of SCC 
NSCLCs, in progression after chemotherapy (Kazandjian et al., 2016). Approval was given 
after a phase III trial, in which nivolumab showed an increased response rate (RR), OS and 
PFS compared to docetaxel in advanced SCCs regardless of PDL-expression status 
(Brahmer et al., 2015). RR was 20 % for nivolumab vs. 9 % for docetaxel (p=0.008), OS 
was 9.2 months vs. 6.0 months (HR=0.59; 95 % CI, 0.44–0.79; p<0.001), and PFS 3.5 
months vs. 2.8 months (HR=0.62; 95 % CI, 0.47–0.81; p<0.001), respectively. 
Pembrolizumab and MPDL3280A are two other promising agents targeting the same PD-
1/PD-L1 pathway; they are currently undergoing clinical trials (Minguet et al., 2016). The 
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CTLA-4 checkpoint inhibitor, ipilimumab, has shown PFS benefit in advanced NSCLC 
over chemotherapy and placebo (p=0.05) in a phase II trial (Lynch et al., 2012), and a phase 
III investigation is ongoing. 
 
 
As only a fraction of all NSCLC patients may benefit from EGFR and ALK inhibitors, there 
is a need for drugs that could benefit these kinds of individuals (Patel et al., 2015). There 
are multiple possible targetable aberrant and/or deregulated molecules in NSCLC cancers, 
such as RTKs of HER2, MET, NTRK1, RET and ROS1, and downstream signaling 
molecules, such as AKT1, BRAF, MEK1, KRAS and PI3K. Some of the potential drugs 
and their investigations are summarized in Table 1 (based on Tsao et al., 2015; Patel et al., 
2015, and Abramson, 2016). 
 
 
Unfortunately, the patients treated with targeted EGFR and ALK inhibitors eventually 
exhibit disease progression and resistance develops to the inhibitors even if the patients have 
enjoyed a good preliminary response. Resistance occurs approximately about 12 months 
after the start of the treatment (Sequist et al., 2011b; Katyama et al., 2012). Although 
resistance mechanisms remain partly elusive, some of the mechanisms are well-known and 
others are plausible but not confirmed. Tumor heterogeneity creates challenges also in 
targeted treatment, as other alterations can be responsible for the resistance, and treatment 
can cause the clonal selection meaning that the cells capable of being resistant to treatment 
start to predominate (de Bruin et al., 2014; Bria et al., 2015). Resistance mechanisms can 
derive from the same or different genes, and activate the same or alternative signaling 
pathways, which can be caused by mutations, amplifications and/or over-expressions, 
various pathway activations, epigenetic changes, or even morphological changes (reviewed 
in van der Wekken et al., 2016). 
There are some well known resistance mechanisms for EGFR-TKIs as is the case with 
other EGFR mutations (Figure 2), e.g. Thr790Met (Pao et al., 2005; Sequist et al., 2011b), 
Asp761Tyr (Balak et al., 2006) and Cys797Ser (Thress et al., 2015), PTEN deletions (Sos 
et al., 2009), mutations in PIK3CA (Sequist et al., 2011b; Tan et al., 2016) and KRAS (Tan 
et al., 2016), HER2 or MET amplification (Engelman et al., 2007; Sequist et al., 2011b; Yu 
et al., 2013), epigenetic changes (Sharma et al., 2010; Langevin et al., 2015), and 
morphological change from NSCLC to SCLC or EMT (Sequist et al., 2011b; Yu et al., 2013; 
van der Wekken et al., 2016). The gatekeeper mutation, Thr790Met, is found in 
approximately 50–70 % of the cases treated with the first-generation EGFR-TKIs (Sequist 
et al., 2011b; Arcila et al., 2011; van der Wekken et al., 2016). This mutation alters the ATP-
binding pocket of EGFR and suppresses TKI binding (Yun et al., 2008). The mutation 
Val843Ile is responsible for resistance to afatinib (second-generation TKI), and Cys797Ser 
to third-generation TKI (Thress et al., 2015; Tan et al., 2016). Activation of another pathway 
can overcome inhibition of EGFR and lead to activation of downstream signaling. For 
instance, the MET amplification which triggers the activation of the ERBB3/PI3K pathway, 
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can be detected in approximately 20 % of the first-generation EGFR-TKI treatment-resistant 
cases (Bean et al., 2007; Engelman et al., 2007). 
Similar mechanisms underlie ALK-TKI resistance. The best established mechanisms 
involve various gatekeeper ALK mutations, such as Leu1196Met and Gly1269Ala, ALK 
and KIT amplification (Katayama et al., 2012), ALK CNVs, mutations in KRAS, and 
activation of ERBB signaling, such as EGFR (Doebele et al., 2012; van der Wekken et al., 
2016), and a very recently reported change from NSCLC to SCLC (Cha et al., 2015; 
Caumont et al., 2016; Fujita et al., 2016). The gatekeeper mutations are found in 
approximately 40 % of crizotinib-resistant NSCLC patients (Doebele et al., 2012). Second-
generation TKIs, ceritinib and alectinib, have been developed which target also the 
gatekeeper (Muller et al., 2016), however, resistance to these compounds also emerges. 
Recent studies have revealed novel secondary mutations in ALK (Katayama et al., 2014; 
Ou et al., 2015) and overexpression/increased activation of HER3, NRG1 (HER3 ligand), 
IGFR-1R (Dong et al., 2016; Isozaki et al., 2016), ALK, MET and EGFR (Isozaki et al., 
2016), as possible mechanisms of resistance. 
As discussed above, novel targeted inhibitors can overcome some of the resistance 
mechanisms. Multiple options of combinational therapies are under investigation to prevent 
resistance (Patel et al., 2015). For instance, EGFR therapy could be combined with 
inhibitors against MET and VEGF (reviewed in Carrera et al., 2014), and it has been 
proposed that ALK positive patients could be treated with heat shock protein 90 (HSP90) 
inhibitors (Sequist et al., 2010; Socinski et al., 2013), since HSP90 is an essential chaperone 
protein for tumor growth and it stabilizes many mutant proteins including the ALK fusion 




Mesothelioma originates in the mesothelium, a thin layer of tissue surrounding body 
cavities. Mesothelioma can be found in the lining of the lung (pleura), abdomen 
(peritoneum) and heart (pericardium). The most common type of mesothelioma derives 
from the pleura accounting for approximately for 70 % of all mesothelioma cases, and the 
second common is peritoneal mesothelioma (~30 % of all cases). Malignant pleural 
mesothelioma (MPM) is a rare, but very aggressive type of cancer with a very poor 
prognosis. (reviewed in Yang et al., 2008, and de Assis et al., 2014a) This thesis focuses on 
MPM. In Finland, approximately 90 new cases are diagnosed annually, the vast majority 
(80 %) in males, and it is likely due to occupational exposure (Yang et al., 2008). The 
relative one year survival rate is approximately 50 %, while the 5 year survival rate is only 
6 % (Engholm et al., 2015). 
An exposure to asbestos is the most important cause for mesotheliomas; the first report 
of an association was described in 1960 by Wagner et al. in South Africa. It has been 
estimated that 80 % of mesotheliomas are linked with asbestos exposure (Yang et al., 2008). 
Asbestos is a group of naturally occurring hydrated mineral silicate fibers with extremely 
durable characteristics. Due to their features, their usage became common during the 
industrial era and they were widely exploited in manufacturing and construction until the 
1970’s (reviewed in IARC 2012b). The two major groups of asbestos are chrysotile (white 
asbestos) and amphibole (blue asbestos), the latter being highly linked to mesotheliomas, 
although the role of chrysotile has remained debatable (Yang et al., 2008; IARC 2012b). 
Inhaled asbestos fibers remain in the lung and evoke an inflammatory reaction e.g. involving 
TNF-α and NF-κB, leading to damage to DNA, and resistance to apoptosis. Asbestos can 
also cause a release of reactive oxygen and nitrogen species (ROS and RNS), which promote 
DNA damage. (Yang et al., 2008; Sekido, 2013; de Assis et al., 2014a) 
Although the use of asbestos is now banned in many developed countries, its widespread 
use in the past century still is reflected in the incidence of MPM due to its very long latency 
time, as long as 50 years can elapse after the exposure until the development of the clinical 
disease. In addition to asbestos, genetic susceptibility, radiation, Simian virus 40 (SV40) 
and some other mineral fibers, such as erionite, have been associated with mesotheliomas. 
(Yang et al., 2008) 
 
 
Although the latency time may be very long, the time from the onset to the diagnosis is 
short, as symptoms arise shortly after disease development. Due to the very aggressive 
nature of mesothelioma, it is often found at an advanced stage. Mesothelioma is also 
diagnosed by computed tomography (CT) and biopsies. Tumors may be classified further 
by using the TNM classification system. (reviewed in van Zandwijk et al., 2013) 
Mesotheliomas are classified into three different groups based on their 
histomorphological features: epithelioid, biphasic and sarcomatoid. The classification 
remained the same in the new WHO Classification as it was in the 2004 edition (Galateau-
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Salle et al., 2016). IHC markers are used to confirm the pathological diagnosis. It is 
particularly important to distinguish epithelioid mesothelioma from carcinomas. Calretinin, 
Wilm’s tumor gene product (WT1) and podoplanin are considered as the most specific 
markers for mesotheliomas. It is recommended to use at least one cytokeratin, two 
mesothelial and two carcinoma-related markers to confirm the diagnosis. (van Zandwijk et 
al., 2013) 
The prognosis differs among subgroups, as the mean OS rates are 18, 11 and 8 months 
for epithelioid, biphasic and sarcomatoid, respectively. In general, three determinants i.e 
tumor histology, cancer spread and the patient’s performance status, are the main prognostic 
factors. (van Zandwijk et al., 2013; de Assis et al., 2014a) 
 
 
Our knowledge of genetic alterations in MM has increased in recent years, but nonetheless, 
the possible asbestos-exposure associated molecular alterations have remained rather 
elusive (Kettunen and Knuutila, 2014). In the early cytogenetic study conducted by Tiainen 
et al. (1989), deletions and translocations in chromosome 1, and losses in chromosomes 1 
and 4 were associated with high asbestos-exposure in mesothelioma. In mesotheliomas, 
frequent deletions in chromosome arms 1p, 3p, 4p, 4q, 6q, 9p, 13q, 15q and 22q can be 
found (Sekido, 2013). Those regions include tumor suppressor CDKN2A/ARF (9p21) and 
NF2 (22q12). In addition to alterations in CDKN2A/ARF and NF2, also BAP1 mutations are 
well-established in MM (Sekido, 2013; Ugurluer et al., 2016). 
Cyclin-dependent kinase inhibitor 2A (CDKN2A)/alternative reading frame (ARF) 
encodes both a cyclin-dependent kinase inhibitor (p16INK4) and an alternative protein called 
p14ARF, both of which are involved in regulating the cell cycle (GeneCards). The former 
phosphorylates and inactivates retinoblastoma protein and thus arrests the cell cycle. The 
latter suppresses the cell cycle by inhibiting the degradation of p53. Alterations, especially 
deletions, of CDKN2A may lead to activation of the cell cycle (Sekido, 2013). CDKN2A is 
deleted up to 80–90 % of MMs (de Assis et al., 2014a). 
Neurofibromatosis type 2 (NF2) encodes Merlin protein that is also involved in the 
regulation of the cell cycle, and its loss/inactivation leads to cell cycle progression 
(GeneCards). Merlin also represses Rac/Pak and FAK (focal adhesion kinase) signaling, 
which regulates cell migration (Poulikakos et al., 2006). Inactivation of NF2 by deletions 
or mutations is found in approximately 40 % of MMs (Sekido 2013; de Assis et al., 2014a). 
NF2 may be inactivated also by other means, such as epigenetic regulation and 
phosphorylation (Sekido, 2013). 
BRCA1-associated protein 1 (BAP1) is a tumor suppressor gene located in chromosome 
3p21.3. The BAP1 protein interacts with many other proteins, and is involved in multiple 
cellular functions, such as histone deubiquitination, cell cycle, chromatin modification, gene 
transcription and DNA repair (GeneCards). Genetic susceptibility is caused by BAP1 
germline alteration, which predisposes to a cancer syndrome (Carbone et al., 2012). In 
addition, somatic BAP1 mutations occur in MMs with an approximated frequency of 20 % 
(Bott et al., 2011; Zauderer et al., 2013). 
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As discussed, RTKs are frequently altered (activated) in cancer and similarly in MM. 
For instance, EGFR and AXL, and also SRC family kinases have been found to be 
aberrantly activated (Sekido 2013). In contrast, TP53 is one of the most frequently mutated 
genes in cancer, but it seems to harbor mutations much less frequently in mesothelioma 
(Sekido 2013; de Assis et al., 2014b). Recent sequencing studies have revealed a genome-
wide allelic loss as well as frequent SETDB1 mutations (Kang et al., 2016), mutations and 
CNVs in CUL1 (Guo et al., 2015), and mutations in SMACB1, PDGFRA, KIT, KDR, HRAS, 
PIK3CA and STK11 genes (Lo Iacono et al., 2015). 
 
 
MM is highly resistant to chemo- and radiotherapy and thus its prognosis remains poor (van 
Zandwijk et al., 2013). Cisplatin plus antifolate chemotherapy is the standard treatment for 
mesothelioma (Vogelzang et al., 2003; van Meerbeeck et al., 2005), but there are no 
guidelines for second-line treatment once disease progression occurs. Since the disease is 
normally only detected at a late stage, combined with its tendency to grow along the 
cavity/organ surfaces without forming distinct tumors, this means that surgery is rarely an 
option (van Zandwijk et al., 2013). Surgery has been found to significantly improve patient 
survival in individuals with malignant peritoneal mesothelioma (Miura et al., 2014). 
Multiple targeted agents have been studied, but results have been unimpressive, and only 
a few drugs have been tested in phase III trials. Of those, VEGF (bevacizumab and 
thalidomide) and HDAC inhibitors (vorinostat) have been investigated in clinical phase III 
trials (reviewed in Hiddinga et al., 2015). Bevacizumab in combination with chemotherapy 
(pemetrexed plus cisplatin) increased OS of MPM patients compared to chemotherapy 
alone: 18.8 months vs. 16.1 months (HR=0.77; 95 % CI, 0.62–0.95; p=0.0167). However, 
bevacizumab evoked also adverse effects (Zalcman et al., 2015). Thalidomide as second-
line treatment for patients whose disease had progressed on chemotherapy, did not improve 
PFS compared to active supportive care: 3.6 months vs. 3.5 months (HR=0.95; 95 % CI, 
0.73–1.20; p=0.72) (Buikhuisen et al., 2013). Similarly, vorinostat as second or third-line 
treatment did not achieve any improvement in OS in comparison to placebo: 30.7 weeks vs. 
27.1 weeks (HR=0.98; 95 % CI, 0.83–1.17; p=0.86) (Krug et al., 2015). 
There are some novel targeted drugs under investigation i.e. podoplanin antibodies, 
CARP-1 inhibitor and cilengitide (reviewed in Hiddango et al., 2015). Podoplanin, a 
transmembrane sialomucin-like glycoprotein, is highly expressed in MPM, and its antibody 
has been found to efficiently inhibit cell growth in MPM cells (Abe et al., 2013). CARP-1 
is a perinuclear phosphoprotein, which regulates cell proliferation and apoptosis signaling, 
and its inhibition by functional mimetics was reported to induce anti-metastatic events in 
MPM cells (Jamal et al., 2014). Cilengtide inhibits cell growth in MPM cells (Cheng et al., 
2014). Understanding the molecular background and aberrations of mesothelioma in more 
detail is important for the development of better therapies and their combinations (Kettunen 





There have been huge advances made in the analytical methods for studying cancer-related 
genetic and epigenetic alterations in the last decade(s). Here, the most basic and widely-
used methods will be presented briefly, with the major focus on NGS methods, as these 
were the main techniques exploited in this thesis. The selection of method depends on which 
alterations need to be assessed as well as the analytical sensitivity of the method and the 
material from which it is to be analyzed. 
 
 
Polymerase chain reaction (PCR) was developed in 1983 as a way to amplify DNA by 
utilizing a temperature-resistant DNA polymerase, synthetic DNA primers, free nucleotides 
and cycles of temperature changes (Mullis, 1990). Nowadays, numerous genetic 
applications rely on PCR. For example, in mutation testing, there are PCR-based 
commercial, customized kits available to amplify only the mutated sequence by using 
specific primers for mutations or blocking the wild-type sequence amplification. Other 
widely used methods are based on hybridization, i.e. the capability of DNA sequence to 
bind to a complementary sequence. Comparative genomic hybridization (CGH) has been 
exploited to investigate CNVs based on comparison of genomic DNA against the reference 
genome (Kallioniemi et al., 1992). In situ hybridization (ISH) makes possible also spatial 
localization of the sequence in the original tissue by utilizing specific labeled probes that 
bind only highly complementary sequences (Langer-Safer et al., 1982). Microarray 
techniques exploit multiplexing and use specifically arranged probes on an array (Chang, 
1983). IHC is another important technique based on the use of labeled specific antibodies 
and the immunological properties of the molecules (Coons et al., 1941). 
 
 
DNA sequencing methods started slowly evolving after the discovery of DNA structure by 
Watson and Crick in 1953. The technique requires the presence of a template DNA sequence 
that is produced according to the complement rules by using DNA polymerase and free 
(modified) nucleotides. The first method to become widely used, nowadays referred to as 
first generation sequencing, was Sanger sequencing (direct sequencing) published in 1977 
(Sanger et al., 1977). In Sanger sequencing, some of the free nucleotides are 
dideoxynucleotides (ddNTPs) at a low concentration, ddNTPs terminate the DNA 
elongation (due to a lack of free 3’ hydroxyl group). One type of ddNTPs is included in the 
sequencing reaction at one time, producing various lengths of DNA fragments which can 
be separated by electrophoresis and grouped by ddNTPS. During the following decades, 
many improvements have occurred e.g. the sequencing became automated, and the 
automated capillary sequencer was developed (reviewed in Heather and Chain, 2016). 
Capillary sequencing was introduced as a shotgun method (Figure 4); this approach was 
used to sequence euchromatin of the human genome, of which 99 % was published in 2004 
(International Human Genome Sequencing Consortium, 2004). 
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The pyrosequencing method represented an important development; this is a direct 
sequence-by-synthesis technique similar to the Sanger procedure. Instead of modified 
nucleotides, this approach was based on the luminescence produced by pyrophosphate (PPi) 
synthesis that occurs naturally once a nucleotide is incorporated. Two enzymes are used in 
pyrosequencing: a pyrophosphate is converted into ATP by ATP sulfurylase, and ATP is 
used as a substrate by luciferase, which produces a luminescent signal detected by camera 
which can be analyzed by a software program. The signal intensity is proportional to the 
numbers of nucleotides that are incorporated. (Ronaghi et al., 1998) 
Subsequently, the molecular methods have developed extensively, for example, first 
generation sequencing methods have been largely replaced with the next generation or even 
the third generation sequencing methods (reviewed in Metzker, 2010, van Dijk et al., 2014, 








The first NGS method, massively parallel signature sequencing, was published in 2000 
(Brenner et al., 2000), followed by 454 Life Sciences sequencing commercialized by Roche, 
and the technology developed in 2004 by Margulies et al. (2005). One common feature of 
all methods is that they have a solid surface where the millions of sequencing reactions 
occur simultaneously. All methods are based on a template preparation from genomic DNA, 
sequencing, detection of results and alignment to the reference genome. NGS methods have 
multiple applications. In genomic DNA sequencing, whole genome, exome, targeted and de 
novo sequencing are used. NGS has revolutionized research investigating the connection 
between genetic variation and phenotype. Recently, a new application for NGS methods 
was developed - it can be utilized in a single cell genomics, for instance, making it possible 
to classify tumor cells according to their genetic features. This provides a deeper 
understanding of tumor development. In addition to genomic sequencing, RNA sequencing 
is available for investigating post-translational modifications, splice variants, gene fusions 
and changes in gene expression. This provides much larger and detailed information 
compared to array technology. (Metzker, 2010; van Dijk et al., 2014; Heather and Chain, 
2016) In this thesis, DNA sequencing methods of targeted and exome sequencing have been 
used on Illumina and Ion Torrent platforms; these will be discussed in more detail in the 





After the 454 Life Sciences (Roche), Solexa (Illumina) (Bentley et al., 2008), new 
techniques were published such as SOLiD (former Life Technologies) (Valouev et al., 2008) 
and Ion Torrent (Thermo Fisher Scientific) (Rothberg et al., 2011). The first step in all NGS 
methods, is the preparation of the library and the template, where the target genomic DNA 
is fragmented, and primers, adapter and barcode oligonucleotides are added to enable 
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specific sequencing chemistry and multiplexing. In amplicon-based NGS, such as the Ion 
Torrent technology, the libraries are size-selected and only those of the correct size are 
amplified by using primers designed for the genes of interest. The Illumina platforms (others 
than amplicon sequencing in Study III) used in this thesis, exploits an in-solution 
hybridization-based selection, where the specific biotinylated complementary probes select 
the library fragments to be amplified. The amplification may take place in emulsion 
(emulsion-PCR) or on a slide. The latter approach is used in Illumina and SOLiD. In the 
Illumina platform, it is performed by bridge amplification, where single stranded library 
fragments attach to the surface of the flow cell, which also includes primer sequences. In 
bridge amplification, the library molecules are amplified once they reach and bind primer 
sequences. The subsequent amplification event occurs close to the primary site, eventually 
forming a group of amplified templates. In emulsion-PCR, exploited by Ion Torrent, SOLiD 
and 454, amplification occurs in a mixture of emulsion oil and PCR mix. Ideally, one 
emulsion droplet contains one library molecule, primers, one bead and the PCR mix. After 
PCR cycles, a bead is covered by multiple copies of one type of library molecule. The library 
of nucleic acid fragments acts as a template for a new DNA to be synthetized. (Metzker, 
2010; van Dijk et al., 2014; Heather and Chain, 2016) 
NGS methods differ in the way they detect the nucleotides which have been incorporated 
into the elongating DNA sequence. The methods currently in use are reversible terminator 
sequencing (Illumina), semiconductor sequencing (Ion Torrent), pyrosequencing (454) and 
sequencing by ligation (SOLiD). Reversible terminator sequencing relies on the presence 
of fluorescently labeled nucleotides that terminate the sequencing reaction. All types of 
those nucleotides are applied in the same cycle and non-incorporated nucleotides are washed 
away. Fluorescent labels are detected by a camera in each flow cell. Before the next cycle, 
fluorescent dye and 3’ terminator are removed. After all of the imaging cycles, the sequence 
is stored as fluorescent colors and mapped to the corresponding bases. (Metzker, 2010; van 
Dijk et al., 2014; Heather and Chain, 2016) 
Semiconductor sequencing does not require imaging, but relies on the detection of a 
change in pH once a nucleotide has been incorporated and a hydrogen ion released. There 
is a sensitive sensor on the bottom of each micro well that contains the DNA template. A 
single nucleotide type is provided at a time, and if the nucleotide is complementary to the 
template, incorporation occurs and an ion release is detected. If more than one nucleotide is 
incorporated, a higher electronic signal is detected. (van Dijk et al., 2014; Heather and 
Chain, 2016) 
The development of NGS methods poses enormous challenges for data management. 
Therefore, sophisticated bioinformatics tools for the data analysis are required. Figure 6 
illustrates the basic workflow of NGS data analysis. NGS methods have proven to be more 
accurate and sensitive at detecting genetic alterations than the more conventional methods, 
such as FISH (Pekar-Zlotin et al., 2015) and Sanger sequencing (Chevrier et al., 2014; Han 
et al., 2014; Belardinilli et al., 2015). Due to high sensitivity and requirement of only a small 
amount of starting material, also archival material (FFPE) and fine needle aspirations can 





Helicos (Helicos Genetic Analysis System), PacBio (Pacific Biosciences) and Oxford 
Nanopore Technologies (Oxford Nanopore Technologies Limited) represent the third 
generation sequencing (TGS) techniques that enable single molecule sequencing in real-
time (SMRT) (Braslavsky et al., 2003; Harris et al., 2008; Pushkarev et al., 2009), whereas 
NGS requires the amplification of single molecules. TGS uses sequencing-by-synthesis 
technology and real-time detection of the fluorescent signal produced by the incorporated 
nucleotides. DNA polymerase initiates the sequencing reaction and the reaction ends when 
the polymerase dissociates from the template. The major advantage of TGS technology is 
the elimination of problems related to PCR and the short read length. Moreover, neither 
complex repeats nor poorly amplified regions pose a problem for the third generation 
technology. (reviewed in Roberts et al., 2013; Heather and Chain, 2016) 
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The general aim was to study cancer-related mutations, their prevalence, concurrences and 
associations with clinical data, in Finnish NSCLC and MM patients, and to confirm the 
feasibility of utilizing next generation sequencing methods in cancer diagnostics. 
The specific aims were to study: 
• Mutations of ephrin receptor genes and their incidence in NSCLC (I) 
• Clinically relevant epidermal growth factor receptor mutations in NSCLC(II) 
• Novel asbestos-related mutations in lung ADC and MM (III) 
• “Hot spot” mutations in AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, 
ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, 




The sample material and methods used in this thesis are only described generally in this 
section (Table 2). The original publications provide more detailed information. 
 
 
FFPE tumor samples were collected from NSCLC patients diagnosed and treated in the 
Helsinki and Uusimaa Hospital District, Finland, during the years 2005 to 2014 (I, II and 
IV). In Study I, 24 samples were obtained from other hospitals in Finland. The majority of 
the patients had undergone surgical procedures. A minority of the samples were obtained 
by core needle biopsy (CNB) or fine needle aspiration (FNA). All the specimens were 
collected before any treatment, and had been evaluated by histology and tumor cell 
percentage by a pulmonary pathologist. Primarily all the samples tested had a tumor 
percentage of 20 % or more. The patient samples selected for Study I had an indication for 
ALK or EGFR testing. In Studies II and IV, samples were collected unselectively: all the 
samples available with sufficient tissue material, extracted DNA and tumor cell content 
were included into this study. In Study III, NSCLC samples represented fresh frozen (FF) 
tumor material. Normal tissue samples were used for validation purposes and were obtained 
from blood, normal adjacent lung or lymph nodes. 
Diagnosis was based on the 3rd edition of WHO Criteria (Travis et al., 2004). In Study 
II, EGFR mutation positive ADC cases were furthermore sub-grouped according to the 
updated IASLC/ATS/ERS classification (2011) (Travis et al., 2011). Based on smoking 
history, patients were divided into the following subgroups: never-smokers, ex-light 
smokers (smoked <20 years but subsequently ceased >10 years ago), ex-medium smokers 
(smoked >20 years but subsequently ceased), and current smokers (smoked >20 years and 
ongoing). Evaluation of occupational asbestos exposure was based on the patient interview 






MM samples were also collected in the Helsinki and Uusimaa Hospital District, Finland, 
between 2007 and 2010, before any treatments. Similarly, the histological diagnosis and 
tumor cell content were investigated by a pulmonary pathologist. In total, 21 samples were 
eligible for inclusion in the study. Of those, all presented epithelioid histology. 
 
 
In all studies, DNA was extracted from FFPE tumor sections by using the QIAamp DNA 
Mini Kit (Qiagen GmbH, Hilden, Germany) with minor changes (Tuononen et al., 2013). 
The quality and quantity of the extracted DNA samples were measured with the Qubit® 
fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). 
In Study II, WaxFreeTM DNA Extraction Kit (Trimgen, Sparks Glencoe, Maryland, 
USA) according to the manufacturer’s instructions for paraffin samples was used for the 
isolation from some FNB and CNB FFPE specimens. 
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In Study III, DNA from FF specimens was extracted by using the QIAamp DNA Mini 
Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s protocol for 
extraction from FF tissue material. 
 
 
In Studies III and partly IV, the asbestos fibers were counted from normal lung tissue 
samples by scanning electron microscopy (SEM) from ADC specimens and by transmission 
electron microscopy (TEM) from MM samples. That was conducted according to the 
standardized method (Tuomi et al, 1992) in the Finnish Institute of Occupational Health, 
Helsinki, Finland. Criteria for patients to be considered as non-exposed were defined as the 
following asbestos fiber contents of dry lung tissue: less than 0.2x106/g and 1.0x106/g for 
MM and ADC, respectively. Asbestos-exposed lung contained fibers more than 1.0x106/g 
and 2.0x106/g in MM and ADC, respectively. 
 
 
In Study I, BRAF, EGFR and KRAS mutation testing was performed by standardized PCR-
based mutation testing kits. EGFR mutations (19 distinct deletions in exon 19, three distinct 
insertions in exon 20, and point mutations of Gly719Ser/Ala/Cys, Ser768Ile, Leu858Arg 
and Leu861Gln) were tested using the TheraScreen EGFR PCR Kit (Qiagen®, Manchester, 
UK), KRAS mutations (Gly12Ala/Asp/Arg/Cys/Ser/Val and Gly13Asp) by the 
TheraScreen KRAS PCR Kit (Qiagen®), and BRAF V600E mutations by the AmoyDxTM 
BRAF V600E Mutation Detection Kit (Amoy Diagnostics, Xiamen, China). In all analyses, 
an ABI7500 instrument (Applied Biosystems, Foster City, CA, USA) was used. 
In Study II, EGFR mutations were investigated by the TheraScreen EGFR PCR Kit 
(Qiagen®; 500 patients) or the cobas® EGFR Mutation Test (Roche Molecular Systems, 
South Branchburg, NJ, USA; 28 patients) on the cobas z480 platform. All the kits were used 
according to the manufacturer’s instructions. 
The Therascreen mutation tests use ARMS® (Newton et al., 1989) and Scorpions® 




In Study I, capillary sequencing was performed on 13 samples with an Eph mutation and 
eligible material for mutation validation. DNA (5–15 ng) was amplified by PCR, and 
capillary sequencing was conducted both on tumor tissue and the corresponding normal 
tissue material of lymph node (eligible from 13 patients). Sequencing was performed on 
ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA) using Big Dye 
Terminator v3.1 cycle sequencing kit (Applied Biosystems, Warrington, UK). Results were 
analyzed on Sequencher 5.1 (Gene Codes Corporation, Ann Arbor, MI, USA). 
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In Study I, 13 ephrin receptor genes, EPHA1-8, EPHB1-4 and EPHB6, were analyzed for 
all exonic regions by targeted NGS. The gene panel had a total of 192 genes, including RTK, 
miRNA and cancer related genes. The target capture consisting of 2 676 regions (~1 Mb) 
was designed by using e-array (Agilent Technologies, Santa Clara, CA) to cover all exons, 
3’UTR and 5’UTR regions of all the genes, and the RNA probes were obtained from 
Agilent. 
Extracted DNA (2–3 μg) was prepared for the sequencing libraries by fragmentation, 
adapter ligation and target enrichment according to the SureSelect in-solution (Agilent) 
target capture and enrichment protocol based on hybridization and bridge amplification. The 
libraries were sequenced by paired-end sequencing on Illumina HiSeq2000 sequencer 
(Illumina, San Diego, CA, USA). 
 
 
In Study III, DNA (1–3 μg) samples were prepared according to the NimbleGen SeqCap EZ 
Exome 2.0 Library SR User’s Guide (Roche) with a few changes to target exonic regions. 
The Covaris S-2 instrument (Covaris, Woburn, MA, USA) was used for fragmentation. Both 
sample types, FFPE and FF were treated similarly. The libraries were sequenced on 
Illumina’s HiSeq2000 sequencer. 
 
 
In Study III, the amplicon deep sequencing was used for validation of the selected novel 
variations detected by the exome sequencing. PCR amplification was performed on DNA 
(10–20 ng) from paired tumor and normal adjacent lung tissue (if available), adapters were 




In Study IV, DNA samples (10 ng) from 425 NSCLC samples underwent library preparation 
by using the Ion AmpliSeqTM Colon and Lung Cancer Panel (Thermo Fisher Scientific) 
together with the Ion AmpliSeqTM Library Preparation Kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. The Colon and Lung Cancer panel covered 
504 mutational hot spots (14.6 kb) in 22 genes: AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, 
ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, 
NRAS, PIK3CA, PTEN, SMAD4, STK11, and TP53. The libraries were quantified with 
Qubit® 2.0 Fluorometer. Template preparation and enrichment were performed by using 
the Ion OneTouchTM 2 system (Thermo Fisher Scientific) and the Ion PGMTM Template 
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OT2 200 Kit (Thermo Fisher Scientific). The sequencing was conducted with the Ion 
PGMTM Sequencing 200 Kit v2, the Ion 316v2 chip and the Ion Torrent PGM instrument 
(Thermo Fisher Scientific). 
 
 
In Studies I and III, the raw NGS data obtained by Illumina HiSeq sequencer were analyzed 
by using an in-house built analysis tool called variant calling pipeline (VCP), developed at 
the Finnish Institute of Molecular Medicine (FIMM) (Sulonen et al., 2011). The VCP is a 
combination of commonly used and in-house algorithms which can quality-filter the data, 
align the sequences utilizing the Burrows-Wheeler Aligner (BWA) (Li and Durbin et al., 
2010) against the reference human genome (h19), remove duplicates, and call variants using 
SAMtools’ (Li et al., 2009) for SNVs and Pindel (Ye et al., 2009) for indels. In Study III, 
prior to alignment, the overlapping paired reads were merged into single longer reads using 
SeqPrep. Only those variants with a read depth ≥6, a phred quality score ≥20 and a quality 
ratio of ≥0.8 were selected into the analysis. For indels, only those with a quality score ≥40 
were included. 
In Study III, the amplicon sequencing data were analyzed at FIMM by using an in-house 
algorithm pipeline including Bowtie2 (Langmead and Salzberg, 2012) to align the 
sequences against the reference (h19), call SNVs with SAMtools’ and BCFtools, and indels 
with GATK IndelRealigner (DePristo et al., 2011). 
In Study IV, the raw data obtained from the Ion Torrent PGM sequencer were analyzed 
with the TorrentSuiteTM Software (v.4.0.2) (Thermo Fisher Scientific). The Variant Caller 
plug-in (v4.0-r76860) (Thermo Fisher Scientific) was used for variant calling with the 
default settings: a quality score ≥6, relative read quality ≥6.5, coverage ≥6 for 
SNP/COSMIC variant and 15 for indel, and strand bias ≤95 % for SNP/COSMIC variant 
and 90 % for indel. The Coverage Analysis plug-in (v4.0-r77897) (Thermo Fisher 
Scientific) was used for coverage analysis. 
 
 
The secondary analysis was performed by diverse steps. In the visualization of data, the 
Integrative Genomics Viewer (IGV) was used (Thorvaldsdottir et al., 2013). Two in silico 
analysis tools, PROVEAN (Choi et al., 2012) and SIFT (Kumar et al., 2009), were used to 
predict the effect of the non-synonymous variants on the encoded protein. 
In Studies I, III and IV, all non-synonymous and indel variants in exonic regions were 
selected for further analysis. The variants reported in NCBI dbSNP (build 135 in Study I, 
build 137/142 in Study III, and build 146 in Study IV) were defined as known variants, as 
well as those not found in either dbSNP or 1000 Human Genomes Project as novel variants. 
In Study III, variants detected in any normal sample were also removed from the analysis. 
In Study III, those mutations or genes that were detected exclusively in asbestos-exposed 
patient samples were selected out of all non-synonymous mutations causing a probable 
damaging effect. The exome data were investigated to find the most frequently mutated 
chromosomal positions and the genes involved. The recurrent variants or recurrently 
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mutated genes were defined as those occurring in three or more asbestos-exposed patients. 
All variants were checked in the dbSNP (build 142) to remove variants reported in a newly 
built database. Moreover, the exome data were studied also for variants (<2 % in the 1000 
Genomes) found in BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, STK11, 
EPHA1-8, EPHA10 and EPHB1-4, EPHB6 for both ADC and MM, plus BAP1, CUL1, 
CDKN2A, NF2 for MM. From amplicon deep sequencing data, the variants with a variant 
base frequency of 0.5 % of all reads in a given position were selected. The base frequency 
was compared to the quality value of the corresponding base. All variants with a frequency 
ratio of ≥0.7 were considered as true variants. 
Study IV, a COSMIC mutation was defined as a mutation found in the Catalogue of 
Somatic Mutations in Cancer. In the secondary analysis, the following filtering threshold 
was set: a frequency of variant allele ≥3 %, and an average phred quality score ≥15 for 
previously known COSMIC mutations and ≥20 for novel variants. 
 
 
All statistical analyses were performed using IBM SPSS Statistics v21 (Study II) or v22 
(Study IV) (IBM Corp., Armonk, NY, USA) software. The investigation of associations 
between clinicopathological features and molecular status was conducted using Pearson’s 
χ2 test, Fisher’s exact test and independent t-test, as appropriate. In Study II, OS was 
estimated by the Kaplan-Meier method with a log rank test to compare the cumulative OS 
between the groups. Two-sided p values <0.05 were considered statistically significant. 
 
 
Ethical permissions for the studies were obtained from the Ethics Committee for the 
Department of Medicine of the Hospital District of Helsinki and Uusimaa, Finland; consent 
no.  370/13/03/01/2010.  
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In total, we examined 106 NSCLC and 22 MM samples for mutations in Ephs by NGS 
targeting the exons of the following Eph genes: EPHA1-8, EPHB1-4, EPHB6 (Studies I and 
III), and EPHA10 on 26 ADC and 21 MM samples in Study III. The stringent thresholds 
used in variant calling produced most likely true-positive variants, although some low-
frequency variants may have remained undetected. In Study I, the average coverage was 
good with a mean of 135 (range 52–300). Moreover, our previous study showed that this 
NGS method produces reliable results compared with the golden standard mutation 
detection methods (Tuononen et al., 2013). In Study III, exome sequencing produced a mean 
target coverage of 38 (range 13–54), and similar thresholds were used. 
When using the newest dbSNP (build 147) as the reference, the total number of novel 
non-synonymous mutations detected in both studies was 27 mutations in 23 patients. Of 
these, four cases were diagnosed with MM, 18 with lung ADC, and one with lung LCC. Of 
the 23 cases with mutations, 74 % (17/23) were males, and even more, 95 % (21/22; with 
known smoking status) were ever-smokers. In Study III, the mutations were detected in both 
asbestos-exposed (n=8) and non-exposed (n=5) patients (the asbestos-exposure status was 
known for 13 patients with a novel Eph mutation). The detected Eph mutations did not 
display any associations with the clinicopathological features. However, the sample set was 
small and thus firm conclusions cannot be drawn. Previously no association between 
mutations and clinical data has been conducted. The overall (novel) mutation frequency was 
18 % (23/128) (Table 3), which is similar to that of the 20 % (37/188) found in a larger 
mutation screening experiment reported by Ding et al. (2008). The 21 rare variants (with 
the reported frequency less than 2 %), were found in 25 patients (including two MMs), 
accounting for 20 % (25/128) of the patients (Table 3). The Ephs were found to be mutated 
with similar frequencies in both NSCLC and MM, although it is noteworthy that the number 
of MM cases was rather small in this study. All missense mutations were predicted as being 
damaging to the protein product by either or both of the in silico tools, with two exceptions: 
EPHB1 Arg368Gly and EPHB6 Arg300Pro were predicted as neutral. Five mutations were 
confirmed as somatic, as they were validated in tumorous sample, but were not present in 
the paired normal sample: EPHA3 Gln676His, EPHA10 Gly260Val and Leu472Met, 
EPHB1 Thr981Met, and EPHB6 Asp653fs. Moreover, seven mutations were validated in 
tumorous tissue (Study I Table 3). The somatic nature remains elusive in most cases due to 









Of the novel mutations, 33 % (9/27) occurred in the protein kinase domain, and two in the 
ligand binding domain of the receptors. Mutations which were predicted to be damaging in 
these functionally essential domains may cause deregulated activation, and changes in 
ligand binding, and thus promote possible oncogenic properties. However, possible 
oncogenic effect of the mutations located at other domains cannot be excluded. In the case 
of EPHA3, many mutations have been demonstrated both in vitro and in vivo to reduce 
kinase activity, ligand binding and downregulate the localization of the receptor on the cell 
surface (Lisabeth et al., 2012; Lahtela et al., 2013). EPHA3 has been described as a putative 
tumor suppressor (Zhuang et al., 2012; Lahtela et al., 2013), but in a later comprehensive 
study, the essentiality of EPHA3 in tumorigenesis of murine lung ADC driven by KRAS or 
TP53 alterations, was not confirmed (Lahtela et al., 2015). 
In particular, mutations in EPHA3 and EPHA5 have been detected frequently in NSCLC 
(Davies et al., 2005; Ding et al., 2008; Imilienski et al., 2012; Saintigny et al., 2012), but 
mutations can be found in any of the Eph family genes (Imilienski et al., 2012; COSMIC) 
and are commonly spread along the gene (Saintigny et al., 2012; COSMIC). In this study, 
the tendency of EPHA3 and EPHA5 to gain mutations could not be confirmed. There is 
evidence that the Eph family mutations, such as EPHA2 mutations have been linked to 
cancer cell invasion and survival, and increased activation of mTOR signaling in SCC cells 
(Faoro et al., 2010). EPHA2 was recently identified as a tumor suppressor in KRAS positive 
ADC, i.e. there was inhibition of the RAS pathway and prevention of tumor cell 
proliferation after EPHA2 activation (Yeddula et al., 2015). Prognostic evidence of 
frameshift mutations of EPHB2 and EPHB4 has been found in colorectal cancer, as the 
mutations were associated with poorer prognosis (Alazzouzi et al., 2005). The exact role of 
Eph mutations remains still largely elusive, although somewhat more is known about altered 
expression statuses of Ephs, also in lung cancer. In NSCLC, elevated expressions of 
EPHA1, EPHA4 (Saintigny et al., 2012), EPHA5 and EPHA7 have been linked to better 
prognosis (Giaginis et al., 2014), whereas that of EPHA2 with a poorer prognosis (Brannan 
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et al., 2009). EPHA4 expression has also been associated with early stages of cancer and 
inflammation (Giaginis et al., 2014), and in another study, it was found to suppress cell 
invasion (Saintigny et al., 2012). Additional tumor suppressive roles have been detected in 
EPHB6, as it decreased metastasis and was silenced by promoter hypermethylation in 
NSCLC (Yu et al., 2010). On the contrary, elevated EPHB3 expression has been associated 
with increased cell growth and metastasis (Ji et al., 2011). Similarly, increased expressions 
of EPHA1, EPHA5 and EPHA7 have been associated with tumor cell proliferation (Giaginis 
et al., 2014). Moreover, EPHA7 expression have been linked to older age, fibrosis and 
smaller tumors (Giaginis et al., 2014), and EPHA2 expression to smoking history, EGFR 
activation (but no mutations) and KRAS mutations (Brannan et al., 2009). It has been 
postulated that Ephs may have different roles in tumorigenesis, and that they may even 
change from oncogenes to tumor suppressors during the course of tumorigenesis (Saintigny 
et al., 2012). 
The rare variant and/or novel mutations in Ephs detected in four MM patients involved 
EPHB1; three with a novel mutation, and one with a rare variant (Study III Table 4; Table 
3). EPHB1 mutations in MM have not been described previously. According to the 
COSMIC database, only one synonymous mutation of EPHB1 has been found in 
mesothelioma (Guo et al., 2015). Similar to the situation with NSCLC, more is known about 
the expression level of Ephs than the role of mutations in MM. Overexpression of EPHB2 
has been found to associate with tumorigenesis of MM (Goparaju et al., 2013). In addition, 
the overexpressions of EPHA2 (Nasreen et al., 2006) and EPHB4 (Liu et al., 2013) have 
been observed in MM. Previously, inhibition of EPHA2 reduced cell growth and migration 
in MM cells (Nasreen et al., 2006). Intriguingly, Ephrin A1 ligand induced activation and 
phosphorylation of EPHA2 receptor and subsequently decreased EPHA2 expression and 
inhibited cell growth via ERK signaling in MM cells (Nasreen et al., 2007). A more detailed 
mechanism was revealed in a later study: Ephrin A1 activation causes let-7 miRNA 
expression, which suppresses the RAS oncogene and consequently tumor growth 
(Khodayari et al., 2011). This finding may be therapeutically interesting since it is known 
that certain tumors overexpress EPHA2 (Lee et al., 2013). In addition, inhibition of EPHB4 
was found to suppress tumor growth, especially in combination with bevacizumab (anti-
VEGF), in MM xenografts (Liu et al., 2013). These findings support the potential of Ephs 
to serve as therapeutic targets. 
Eph mutations were frequently found simultaneously with other mutations in driver 
genes, such as KRAS, EGFR, PI3K, and there was also one concurrent case with the ALK-
EML4 fusion gene (Study I Supplemental Table S2; Study III Table 3). The prevalence 
together with the driver mutations suggests that they have more of a passenger role, although 
other possibilities e.g. enhancing driver capabilities of other alterations, cannot be excluded 
due to the involvement of Ephs in so many signaling pathways. For instance, EPHA3 
mutations co-occurred with TP53 mutations statistically significantly in ADC, and some 
trend of concurrence was observed with KRAS mutations (Lahtela et al., 2015). 
In this study, prognostic significance was not studied. However, two of those patients 
harboring a concomitant activating EGFR mutation and Eph mutation, were treated with 
EGFR-TKI and in both cases the disease continued to progress and survival was 15–18 
months (Study I Supplemental Table S2). One patient harboring EPHA1 Arg844fs deletion 
and EGFR Leu858Arg, did show some response to treatment with gefitinib, but the disease 
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progressed. Another patient harboring EPHA5 G209R and EGFR exon 19 deletion was 
treated with gefitinib (after a relapse with erlotinib), and after a moderate response, the 
disease progressed. 
In conclusion, Ephs clearly represent a significantly mutated receptor family in lung 
cancer and due to their diverse roles in modulating cell function especially their potential 
oncogenic and tumor suppressive roles, they can be viewed as a very intriguing group from 
a prognostic and therapeutic point of view. The studies on mutation and expression statuses 





EGFR mutations are clinically significant in NSCLCs, and nowadays mutation testing is a 
routine part of diagnostics. Those patients harboring certain activating EGFR mutations are 
likely to respond to treatment with EGFR-TKIs. 
In Study II, the EGFR mutation detection was performed with real-time PCR kits. The 
Therascreen EGFR PCR Kit produced valid test results as follows: 100 % (429/429) of the 
biopsy DNA samples, 95 % (37/39) of the CNB DNA samples, and 56 % (18/32) of the 
FNA DNA samples. Similarly, cobas EGFR Mutation Test produced the following valid 
results: 100 % (25/25) of the biopsy DNA samples, and 67 % (2/3) of the FNA DNA 
samples. Failed samples included FNA and CNB specimens, from which it is difficult to 
isolate DNA due to the small amount of tissue. In Study IV, mutations were investigated by 
targeted NGS on the Ion Torrent platform. Valid data was obtained from 425 out of 442 
samples. This will be discussed in more detail in section of 5.4. 
In summary, EGFR mutations were found in 11 % (58/510) of the patients, in Study II, 
and in 8 % (34/425) in Study IV. When combining the data, a total of 655 NSCLC samples 
were tested for EGFR mutations giving rise to a mutation frequency of 11.1 % (73/655). 
This is similar to, or close to, the highest frequencies, reported in Western or Central 
European patient cohorts (4.9–13.8 %) (Smits et al., 2012; Boch et al., 2013; Gahr et al., 
2013; Ramlau et al., 2015; Skov et al., 2015). 
In Study II, all mutated cases were diagnosed with ADC (Study II Table 1), and the new 
IASLC/ATS/ERS (2011) classification was used for the EGFR positive tumors. Eligible 
tumor material was available from 54 out of the 58 cases in which it was possible to 
determine ADC subgroup reliably: 98 % (53/54) were invasive ADCs and 74 % (40/54) 
were acinar predominant. With respect to the samples with acinar predominance, a mixed 
type was found in 18 samples: ten with papillary, of which one also displayed a 
micropapillary pattern and one with all four patterns; four with lepidic; three with a solid 
pattern; and one with non-mucinous minimally invasive ADC (MIA). Other predominance 
patterns of invasive ADCs were: lepidic (9 %, 5/54), solid (7 %, 4/54), micropapillary (4 %, 
2/54) and papillary (4 %, 2/54). One EGFR positive ADC was classified as non-mucinous 
minimally invasive ADC (MIA). 
Other investigators have also addressed this issue; Russell et al. (2013) found acinar and 
micropapillary subgroups to harbor most commonly EGFR mutations, however, there are 
many controversies about the association between EGFR mutations and ADC subgroups. 
Some recent studies have suggested that there may be a micropapillary subgroup (Li et al., 
2013; Sun et al., 2014) and another lepidic subgroup which are most predominant in EGFR-
mutant ADCs (Li et al., 2013; Villa et al., 2014). The variation may plausibly be due to 
differences in ethnic background, gender, smoking status and other features. Thus, no firm 
conclusions can be drawn, although it does seem that the EGFR mutation status does not 
correlate with any ADC subgroups. The classification is prognostically important (Russell 
et al., 2013; Sun et al., 2014; Xu et al., 2015). 
In Study IV, four EGFR mutation positive cases were diagnosed with non-ADC 
histology: two SCCs (Leu858Arg and Val774Met), one LCC (Gly719Ala), and one NOS 
NSCLC (Ala767Val). Although EGFR mutations are strongly associated with ADC 
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histology (Dearden et al., 2013), they are occasionally found in other histologies (Dearden 
et al., 2013; Gahr et al., 2013; Ramlau et al., 2015; Skov et al., 2015). 
When comparing the patients’ other clinicopathological data and EGFR mutation status, 
in both studies, statistically significant associations were found between EGFR mutations 
and female gender (p<0.001) and never/light-smokers (p<0.001). However, mutations were 
also detected in smokers. With respect to the EGFR positive patients (n=73), 33 % (n=24) 
were never-smokers, 19 % (n=14) ex-light smokers, 29 % (n=21) ex-medium smokers and 
19 % (n=14) current smokers. EGFR mutations and their higher prevalence in never-smoker 
and female patients have been observed from the very first EGFR mutation studies 
(Shigematsu et al., 2005) to more recent systematic reviews (Dearden et al., 2013; Midha et 
al., 2015). Nevertheless, the mutations occur also among (ex-)smokers (Dearden et al., 
2013; Midha et al., 2015), although it has been claimed that a lower mutation frequency is 
likely in those subjects with a higher tobacco consumption status (Li et al., 2013). In 
addition to those well-known characteristics, in Study II, the mean age of patients with 
EGFR mutations was higher compared than that of the patients with wild-type EGFR 
(p=0.001). 
Of the mutations detected, deletions in exon 19 and missense mutations Leu858Arg in 
exon 21 (as single mutations) were the most frequent, accounting for 71 % (52/73) of the 
EGFR mutation positive cases (Figure 7). This is very similar to the frequency that has been 
reported in previous studies on European patients (59–85 %) (Smits et al., 2012; Boch et 
al., 2013; Gahr et al., 2013; Skov et al., 2015). Compound EGFR mutants were found in 
seven cases in the following combinations: Gly719Ala+Ser768Ile in two cases, 
Gly719X+exon 20 insertion in two cases, Leu858Arg+Ser768Ile in one case, 
Leu858Arg+Asp761Tyr in one case and Leu858Arg+Ala871Thr+Gly735Ser in one case. 
Compound mutants have been reported in many studies, and their proportion of EGFR 
mutated cases has been estimated as between 5 to 25 % (Hsieh et al., 2006; Hata et al., 2010; 
Kobayashi et al., 2013; Keam et al., 2014; Stone et al., 2014; Peng et al., 2015; Kim et al., 
2016). Their possible clinical significance remains obscure. They have been linked to poorer 
prognosis (Kim et al., 2016), but conflicting observations have been made and it is not clear 
whether those patients with a classical activating mutation combined with a rare mutation 
exhibit a similar response to treatment with EGFR-TKIs compared to the patients with 
classical activating mutations alone (Kobayashi et al., 2013; Keam et al., 2014; Peng et al., 
2015). Some studies have shown that the differences in response do seem to depend on the 






In Study II, EGFR mutations were detected in 11 % of the asbestos-exposed patients vs. 10 
% in non-exposed group (p=0.498). In Study IV, no EGFR mutations were seen in asbestos-
exposed group, but the number of the exposed patients was rather small (n=29) and 
statistical significance was not found (p=0.146). This suggests that EGFR mutations do not 
have any association with asbestos-exposure, or may be slightly more prevalent in non-
exposed patients. This is concordant with a previous study by Andujar and colleagues 
(2013), who did not observe any difference in the EGFR mutation prevalence between 
asbestos-exposed (2/50) and non-exposed NSCLC (6/50). 
In Study II, the association between EGFR mutation status and chronic obstructive 
pulmonary disease (COPD) was also assessed. EGFR mutations were seen more often in 
the patients without COPD: 13 % (51/399) vs. 6 % (7/111), suggesting that EGFR mutations 
occur less frequently among COPD patients (p=0.057). This finding is in good agreement 
with other studies, where the prevalence of EGFR mutations has been higher in non-COPD 
patients, varying between 15–37 %, compared to 5–16 % in COPD patients (Suzuki et al., 
2010; Lim et al., 2015; Saber et al., 2016). 
In Study II, the median follow-up time was 23 months (range 0–112). Overall, data from 
65 % of the patients was eligible and suitable for survival analysis. There was no statistical 
difference detected in OS between ADC patients with wild-type EGFR (68.6 months; 95 % 
CI, 62.6–74.7) and ADC patients with the mutated EGFR (52.2 months; 95 % CI, 40.2–
64.2, p=0.460) (Study II Figure I and Table 3). Similarly, no statistical differences were 
seen in OS between EGFR mutation positive and negative patients when only non-smoker 
ADC patients were analyzed. Whether or not EGFR mutation is a prognostic marker 
remains controversial. In a recent systemic review of 22 studies and a meta-analysis 
evaluating 16 reports of early-stage resected NSCLC, no statistically significant prognostic 
role of EGFR mutations was found in OS (p=0.12) or PFS rates (p=0.65) (Zhang et al., 
2014). This supports our finding, although the follow-up time was rather short and a large 
number of patients were still alive at the termination of this study. 
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Clinically significant EGFR mutations have been commonly reported to be mutually 
exclusive with other driver alterations, such as ALK-EML4 fusion, BRAF Val600Glu and 
KRAS mutations (Dearden et al., 2013; Gainor et al., 2013; Tissot et al., 2016). EGFR 
mutations were found to be significantly mutually exclusive with KRAS mutations as well 
as with the ALK-EML4 fusion in ADC patients (Dearden et al., 2013). This was also seen 
in this study with one exception. In Study IV, we identified one patient with a total of 15 
hot spot mutations including EGFR Leu858Arg and KRAS Gly13Cys. Concurrences of 
driver alterations are seen occasionally (Ulivi et al., 2015; Lee et al., 2016; Sahnane et al., 
2016), and for instance, a concurrent KRAS mutation with the ALK fusion has been 
proposed to be a marker of a poor prognosis (Ulivi et al., 2015). 
These two separate analyses on partly overlapping material also provided an opportunity 
to investigate the concordance of the results obtained by real-time PCR and targeted NGS. 
Briefly, a concordance of 99.7 % was obtained when considering only the mutations 
detectable by the PCR kit. Only one discordant case, i.e. a Gly719X mutation was detected 
in one sample by PCR, but not by NGS. However, this produced only a weak signal in PCR 
and was assessed as being unclear. We noted other advantages with NGS i.e. two insertions 
in exon 20 which were not included in the PCR panel were detected by NGS. These results 
confirm NGS to be highly sensitive method, and at least comparable to the so-called golden 
standard PCR methods. Results of this comparison are published in Mäki-Nevala et al. 
(2016), and are in agreement with previous studies (Belardinilli et al., 2015; Malapelle et 
al., 2015; Fujita et al., 2015).  
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Asbestos is an important occupational carcinogen and a major cause of MM, a very 
aggressive form of cancer with a dismal prognosis. It should be noted that lung cancer may 
also be caused by exposure to asbestos. Although the molecular features are rather well 
established in ADC and MM, it does seem that asbestos-exposure related alterations have 
remained obscure. 
We performed exome sequencing on 47 tumor specimens including 26 ADC and 21 MM 
(19 pleural and two peritoneal) cases, and nine paired normal samples of ADC patients. 
Exome sequencing could be performed successfully on all samples. The mean target 
coverage was 38 (range 13–54), for FFPE samples it was 37 (range 13–54) and for FF 
samples 39 (range 20–54). The exome data were filtered through various steps, and 
eventually eight genes were identified as possibly being associated with asbestos-exposure: 
BAP1, COPG1, INPP4A, MBD1, SDK1, SEMA5B, TTLL6 and XAB2 (Study III Table 2). 
These genes were exclusively mutated in more than two samples of asbestos-exposed 
patients, and harbored novel variants which were predicted as damaging, and not reported 
in dbSNP or any paired normal sample. 
BAP1 mutations, and SDK1 Gln963Ter were validated as somatic by amplicon 
sequencing, as they were present in tumorous tissue, but not in paired normal tissue material. 
For one BAP1 mutation positive case, paired normal tissue was not available, but the 
mutation was validated in tumor material. Moreover, the following mutations were 
reproducible in tumor tissue: COPG1 Cys230Arg, INPP4A Lys954Arg, SEMA5B 
Thr1040Pro and TTLL6 Glu56fs. The MRPL1 Tyr87Cys mutation was not found in one 
paired normal sample supporting its somatic nature, but unfortunately sequencing was not 
successful in the corresponding tumor tissue material. These genes with some supportive 
evidence for their somatic and/or true positive nature will be discussed in more detail below. 
A recurrent novel mutation was found in mitochondrial ribosomal protein L1 (MRPL1) 
(Tyr87Cys) occurring exclusively in three asbestos-exposed patients, in two MM and one 
ADC. Six MRPL1 mutations confirmed as being somatic have been reported previously; 
four in ADC and two in SCLC histology (COSMIC, 08/05/2016). No mutations have been 
reported to occur in pleura. MRPL1 is a nuclear gene encoding a 39S subunit of the 
mitochondrial ribosome (mt-rRNA) and is thus involved in peptidyl transferase activity in 
mitochondrial protein synthesis (Elson et al., 2015). Its role in cancer has not been 
described, and it can only be speculated that mutations may lead to dysfunction of some 
mitochondrial protein translational event. The mitochondrial genes encode proteins 
involved in cell metabolism, and these kinds of alterations are one hallmark of cancer 
(Weinberg and Hanahan, 2011). 
ROS species derive from cell metabolism and are especially intriguing in asbestos-
related cancer, as asbestos is known to induce inflammation in the lungs and trigger the 
production of ROS species (reviewed in Sekido, 2013). With respect to the mutated genes, 
also sidekick cell adhesion molecule 1 (SDK1) and inositol polyphosphate-4-phosphatase 
type I A (INPP4A) have been related to oxidative stress. INPP4A is involved in 
dephosphorylation of second messenger molecules (inositols) that regulate various 
signaling pathways. For instance, the PI3K/AKT pathway, which is commonly altered in 
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lung cancer, and phagocytosis are negatively regulated by INPP4A (Ivetac et al., 2009; 
Nigorikawa et al., 2015). Activation of PI3K/AKT pathway can promote oxidative stress 
(Kim et al., 2005). Phagocytosis is also an event linked to molecular pathology of MM, as 
macrophages engulf, but do not seem capable of disposing of asbestos fibers and this 
promotes increased production of ROS species (Sekido, 2013). INPP4A has been predicted 
as a candidate gene in asthma, and some polymorphisms in this gene plausibly inhibit 
INPP4A function (Sharma et al., 2008). Moreover, the gene has been observed to serve as 
an important regulator in inflamed lungs of mice (Agrawal et al., 2009; Aich et al., 2012a 
and b). 
SDK1 is a cell adhesion molecule that has been found to be expressed during the cellular 
stress induced by stress signals, particularly ROS species. Its expression is controlled by at 
least two transcription factors, signal transducer and activator of transcription 3 (STAT3) 
and nuclear factor-κB (NF-κB) (Yoon et al., 2012). SDK1 is located at common fragile site 
of the genome, which is prone to break in cancer (Bosco et al., 2010). More recently, somatic 
mutations of SDK1 have been detected in ADC (Imilienski et al., 2012), and in another 
study SDK1 was predicted to be a putative driver gene in lung ADC, particularly if there is 
a mutation G399D (Zhao et al., 2014). Moreover, recurrent somatic mutations were detected 
in adrenocortical carcinoma (Juhlin et al., 2015), and most intriguingly SDK1 was predicted 
to be associated with an increased MM risk in Australian patients (Cadby et al., 2013). These 
findings suggest that SDK1 should receive more attention in the future, as it may be an 
important actor in tumorigenesis. 
Mutations in BAP1 and COPG1 occurred only in MM patients, but as asbestos-non-
exposed cases of MM are very rare, no firm conclusions about their association with 
asbestos-exposure can be drawn. BAP1 mutations are well-established in MM, both as 
germline (Testa et al., 2011) and somatic (Bott et al., 2011: Yoshikawa et al., 2012; Zauderer 
et al., 2013). BAP1 is a nuclear ubiquitin C-terminal hydrolase that interacts with multiple 
proteins, and thus is involved in many cellular functions, such as in chromatin modeling, 
DNA damage, cell cycle and growth (Eletr et al., 2011). The mutations detected in this study 
have not been reported previously in MM, but are located in a region which contains the 
ubiquitin carboxyl hydrolase (UCH) site of the protein, which is frequently found to be 
mutated in MM (Bott et al., 2011), supporting their pathological role. 
Coatomer protein complex subunit gamma 1 (COPG1) encodes a subunit in a coatomer 
protein complex involved in vesicle transport in protein secretion (Hahn et al., 2000). 
Increased expression of alpha subunit of the same complex was observed in mesothelioma 
cells (but not in pleural cells), and its knockdown was associated with a tumor suppressive 
role and apoptosis (Sudo et al., 2010). Previously, COPG has been found to be highly 
expressed in both lung cancer cells and lung cancer-derived endothelial cells (Park et al., 
2008). Mutations of subunits involved in this protein complex are not well-established, 
although some have been reported in COSMIC. 
Semaphorin 5B (SEMA5B) encodes for a member of the semaphorin protein family; it 
regulates the development of the nervous system. Somatic mutations in SEMA5B have been 
reported in various tumors, also in lung and pleura (COSMIC), but their role is unknown. 
However, SEMA5B was proposed to be a candidate gene for susceptibility of esophageal 
carcinoma in a Chinese population (Wu et al., 2011b). Hirota et al. (2006) noted that 
SEMA5B knockdown decreased the renal cell carcinoma cell viability which was 
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interpreted as evidence for an oncogenic role. Multiple other members of semaphorins are 
associated with tumorigenic events, such as angiogenesis (reviewed in Worzfeld and 
Offermanns, 2014). 
Tubulin tyrosine ligase-like 6 (TTLL6) encodes a protein involved in apoptosis, and that 
is overexpressed particularly in the testis (Chen et al., 2006). Somatic mutations similarly 
have been reported occasionally in lung tumors (COSMIC), but their possible role and the 
whole gene’s role in cancer have remained elusive. 
We studied some genes which can function as drivers and/or are known to be mutated 
in lung ADC and/or MM. Those were: BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, 
PIK3CA, STK11 for both ADC and MM, plus BAP1, CUL1, CDKN2A, NF2 for MM. The 
mutations predicted as damaging were detected in Study III (Table 3): BRAF (only ADC), 
EGFR, ERBB2 (only ADC), KRAS (only ADC), MET (only ADC), STK11, BAP1 (only 
MM) and NF2 (only MM). The most frequently mutated genes were KRAS (nine ADCs), 
BAP1 (four MMs) and STK11 (two ADCs and one MM). As a vast majority (25/26) of the 
ADC patients were smokers, KRAS mutations can be expected to occur frequently (Dearden 
et al., 2013). This may be the reason why we failed to find any sign of activating EGFR 






Particular regions in the genome are more prone to harbor cancer-related somatic mutation, 
these kinds of regions are called mutational hot spots. We studied the hot spots of 22 lung 
cancer-related genes in 425 NSCLC patients. Study was conducted on FFPE samples by 
targeted NGS using a panel including the following genes: AKT1, ALK, BRAF, CTNNB1, 
DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, 
NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11 and TP53. This screening study is the 
first to examine a Finnish NSCLC patient cohort. Due to the history of genetic isolation, 
and the fact that certain somatic mutations are associated with ethnic background, the 
Finnish NSCLC patients serve as an attractive study material. 
The sequencing was performed on 442 tumor samples, data from 425 met the predefined 
quality criteria. The resulted samples had an average coverage of 1623 (range 146–4137). 
The samples discarded from the analysis included those with low sequencing coverage 
and/or libraries with low DNA concentration. 
The mutations were divided into those reported in COSMIC (referred to as COSMIC 
mutations), and novel mutations including those not reported in dbSNP or COSMIC 
databases. COSMIC mutations were seen in 77 % of the patients. The majority of mutation 
positive patients (46 %) carried one mutation, 25 % had two mutations, and the others 
harbored from three up to 15 mutations. The most frequently mutated gene was TP53 with 
a frequency of 46 %, as was expected (Dearden et al., 2013; Cancer Genome Research Atlas 
Network, 2012 and 2014). The second most commonly mutated gene was KRAS (26 %) and 
the third was MET (15 %) (Study IV Figure 1 and 2, and Table 2). No COSMIC mutations 
were detected in the following genes included in the panel: ALK, DDR2, FGFR1, FGFR2, 
MAP2K1 and SMAD4. However, non-synonymous novel mutations predicted as damaging 
were detected in those genes (Study IV Supplemental File S1 and Figure 2a). 
A total of 195 non-synonymous novel variants were detected and nearly half (n=93) 
were predicted to be damaging to the protein product (Study IV Supplemental Table S1). It 
is worthwhile highlighting some of these novel variants; they included some probable 
pathogenic variants, such as two EGFR exon 19 deletions, and one ERBB2 exon 20 
frameshift insertion. ERBB2 exon 20 insertions are potentially sensitive to HER2 inhibitors 
(Mazieres et al., 2016). EGFR exon 19 deletions are sensitive to EGFR-TKIs, and they are 
believed to represent their own entity and differ from the Leu858Arg mutation positive 
NSCLCs (Lee et al., 2015). 
The mutations and their incidence resembled largely that described in Western NSCLC 
cohort previously. Some differences can be pointed out, such as a high frequency of BRAF 
and MET mutations and a lower frequency of ERBB2 and STK11 mutations. BRAF 
mutations were found in 5.6 % of the patients, as the reported average frequency in NSCLC 
is approximately 3 % (Chen et al., 2014). However, the proportion of Val600Glu mutations 
was much lower in this study. It has been found to account for approximately a half of the 
BRAF mutants in NSCLC; in this study, the proportion of Val600Glu mutants was only 17 
% (4/24). The total frequency of BRAF Val600Glu was only 0.9 %, the reported frequencies 
being around 2 % (Brustugun et al., 2014). BRAF mutants found in this study occurred in 
amino acid residues from 466 to 605 (Study IV Table 2). The most frequently mutated was 
codon 469 with nine mutated cases. The clinical significance of BRAF mutants in NSCLCs 
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remains unclear (Tissot et al., 2016), although the mutations have been shown to alter 
protein activity (Davies et al., 2002; De Falco et al., 2008; Dahlman et al., 2012). 
Previously MET mutations have been reported in 7 % of ADCs (Cancer Genome 
Research Atlas Network, 2014), while in this study, these kinds of mutations were found in 
16 %. The mutations (Asn375Ser and Thr1010Ile) found in this study are also present in 
dbSNP, so their somatic nature remains questionable. However, the Thr1010Ile mutation 
was detected at a higher frequency in this NSCLC cohort than has been reported for the 
Finnish population in 1000 Genomes (NCBI Genomes Browser) (6 % vs. 2 %). The 
association of Asn375Ser with lung cancer tumorigenesis or prognosis is disputable, one 
study finding its association with a shorter PFS (Cao et al., 2014), but this has not been 
confirmed (Shieh et al., 2013). Similarly, the Thr1010Ile mutation has been proposed to 
contribute to aggressive behavior in breast cancer (Liu et al., 2015) and lung cancer cells 
(Ma et al., 2003; Tengs et al., 2006), but conflicting results have been reported (Schmidt et 
al., 1997; Tyner et al., 2010). Thus, their role in lung cancer remains undetermined. In this 
study, their high frequency and concurrence with driver mutations suggests that they have 
a germline origin, although they may affect prognosis and tumorigenesis. 
The concurrences of COSMIC mutations were also studied (Study IV Table 3; Table 4). 
TP53 mutations were very frequently detected together with other variants, also with 
pathogenic KRAS and EGFR mutations. There is no consensus on whether TP53 mutations 
are prone to occur with other mutations. In a recent meta-analysis, TP53 mutations were 
seen together with EGFR and KRAS in 7.3–7.8 % of the patients, respectively (Dearden et 
al., 2013). On the other hand, in a comprehensive molecular screening of lung ADC, TP53 
mutations were more rarely seen with oncogenic EGFR, KRAS and BRAF (Cancer Genome 
Research Atlas Network, 2014). Previously, STK11 mutations have been found to be 
associated with KRAS mutations (Koivunen et al., 2008; Dearden et al., 2013; Pecuchet et 
al., 2015), and also with TP53 (Dearden et al., 2013), a tendency which was also seen in this 
study. The high frequency of mutated TP53 found here might be one reason for its higher 
concurrence with other gene mutations, and/or the fact that mostly early stage of NSCLCs 
were studied. It has been suggested that the stage of the disease may affect the prevalence 
of TP53 mutations, but it is far from clear whether TP53 mutations emerge at earlier or late 
stages of the disease (Rivlin et al., 2011). Barnett’s et al. (1999) prospective study on 
esophageal ADC suggested that they occur at early stages in tumorigenesis. Moreover, TP53 
is the most commonly mutated gene in many cancers, i.e. in approximately 50 % of all 
cancers (Hollstein et al., 1991), and similarly NSCLC (Dearden et al., 2013) carry mutated 







There were also other COSMIC mutations in addition to EGFR, e.g. statistically significant 
associations were found between PIK3CA (p=0.016) and TP53 (p<0.001) mutations and 
SCC histology, and KRAS mutations and ADC (p<0.001). The CTNNB1 mutations seemed 
to be more likely to be present in light ex-smokers (p=0.011) (Study IV Table 4; Table 5). 
The associations between PIK3CA and TP53 with SCCs are well-established (Dearden et 
al., 2013; Li et al., 2014b), as is the link between KRAS mutations and ADC (Dearden et 
al., 2013). The significance of smoking status and its possible association with mutations 
remain to be clarified. In this study, no mutation other than EGFR and CTNNB1 was found 
to be significantly associated with smoking status, the latter has not been described before. 
Although statistical significance was found, the number of CTNNB1 positive cases was still 
rather small. There were some tendencies, such that TP53 mutations would be more 
common among smokers, which was also an observation in a recent meta-analyses on lung 
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cancer (Liu et al., 2014) and esophageal cancer (Wu et al., 2015). KRAS mutations have 
been found more often in smokers (Dogan et al., 2012), but in this study, no clear association 
was detected, although the mutation incidence was somewhat higher among ever-smokers 
compared to never-smokers (27 % vs. 18 %, p=0.334). 
No association was found between the likelihood of asbestos-exposure and COSMIC 
mutations. However, some tendency was detected with respect to the TP53 and EGFR 
mutations, the latter has been discussed in section 5.2. TP53 was more frequently mutated 
among the asbestos-exposed group (46 % vs. 62 %, p=0.118). In the previous study of 
Andujar et al. (2013), no statistically significant difference was found in the prevalence of 
EGFR, KRAS or TP53 mutations between asbestos-exposed and non-exposed NSCLCs. 
However, some TP53 polymorphisms were associated with asbestos-exposed patients 
(Andujar et al., 2013). In some earlier studies, TP53 mutations have been reported to be 
more prevalent in asbestos-exposed patients (Wang et al., 1995), although in another study, 
no statistical difference could be seen (Husgafvel-Pursiainen et al., 1999). Other clinical 
factors, as well as the method used to determine asbestos-exposure, and less-sensitive 
mutation testing may play a role, and introduce variation into those studies which have 
usually been conducted on a relatively small numbers of cases. 
Due to the short follow-up time and the fact that many of our patients were alive at the 
end of the follow-up, it was not deemed feasible to conduct a survival analysis, but some 
observations can be made. Patients with multiple mutations were observed to die more 
frequently due to lung cancer compared to patients carrying fewer mutations (53 % of the 
patients with more than three mutations vs. 20–37 % of patients with two, one or no 
mutations). Bria et al. (2015) have also reported the association of multiple mutations and 








In this study, a large series of more than 400 Finnish NSCLC and MM patients were studied 
for molecular genetic markers by estimating their frequencies, concurrences and 
associations with clinical data from the patients. The principal methods used in this study 
were NGS, and PCR-based mutation testing. 
In Studies I and III, Eph genes were often found to be mutated, novel mutations were 
found with a frequency of 18 %. Mutations were seen in both lung ADC and MM patients. 
All MM cases harboring either a mutation or a rare variant of Eph, carried the 
mutation/variant in EPHB1. Eph mutations did not associate with clinical features, such as 
smoking status, gender or asbestos-exposure. Ephs are an intriguing group of proteins from 
a therapeutic point of view, as they are involved in a complex network of signaling pathways 
and play diverse roles in many crucial cellular functions, such as in cellular adhesion and 
angiogenesis. Moreover, due to the associations between their altered expression and 
pathogenic features and/or prognosis of the patients, they may serve as novel biomarkers 
for patient management. Thus, they may be a crucial component of the tumorigenesis 
process and could be targeted by drugs. As confirmed here, they are frequently mutated in 
lung cancer specimens; clearly more needs to be known about these alterations as well as 
how these changes alter cellular functions. 
EGFR mutations were found in 11 % of the NSCLC patients. These mutations were 
significantly associated with never- or light-smoking status, female gender and 
adenocarcinoma histology, in accordance with previous studies. However, mutations 
occurred occasionally also in non-ADC histological subgroups and even in current smokers. 
Thus, this study also strongly suggests that histological subgroup or smoking status should 
not be an indication for determining whether or not the subject should undergo EGFR 
mutation testing. In addition, multiple compound EGFR mutants were found, accounting 
for 10 % of mutation positive NSCLCs. 
Study III on asbestos-exposure associated mutations was one of the first studies 
indicating that there seemed to be some molecular differences, also at the level of the DNA 
bases, between asbestos-exposed and non-exposed lung cancer patients. It appears that all 
of the asbestos-exposed patients harbored mutated genes related to oxidative stress, which 
is one outcome of asbestos-exposure. However, known driver mutations, such as those in 
KRAS, do not seem to associate with asbestos exposure. Nevertheless, some genetic 
alterations in asbestos-exposed lung cancer are apparently different from those present in 
non-exposed individuals, and by clarifying their nature, it may be possible to devise novel 
therapy strategies against these very aggressive mesothelioma tumors. 
The mutations in the genomic regions that are prone to cancer-related mutations (hot 
spots), seem to occur in Finnish NSCLC patients similarly as those in their counterparts in 
other Western countries. Some differences were observed, such as a higher overall incidence 
of BRAF mutations, but a lower incidence of the BRAF Val600Glu mutation. The most 
frequently mutated genes were TP53 (46 %) and KRAS (26 %). The concurrence of TP53 
mutations with other hot spot mutations was very evident. A total of 77 % of the NSCLC 
patients carried one or more hot spot mutations.  
Overall, this thesis provides comprehensive knowledge of the mutation spectrum present 
in Finnish NSCLC patients. The novel mutations found in this study provide material for 
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future studies on molecular investigation of lung cancer since they may represent important 
markers for tumorigenesis and it would be beneficial to clarify their associations and 
concurrences since this could help to develop novel targeted therapies. The studies revealed 
the benefits of NGS technology for investigating cancer-related mutations in archival FFPE 
material. The great advantage of NGS is that it is possible to examine multiple mutations, 
both novel and known, in great detail and in different genes simultaneously during a single 
test run. NGS was also found to be at least as sensitive as the golden standard PCR methods. 
In the future, one major focus will be on developing combined targeted therapies, based 
on predictive markers and comprehensive molecular testing. NGS methods are gradually 
replacing the standard methods in cancer diagnostics. It is important to reveal NSCLC 
patients’ molecular characteristics in addition to the histological and morphological features 
of their tumors if one wishes to deliver the optimal therapy with the best prognosis. A 
knowledge of concurrences of the alterations and in particular, possible resistance 
mechanisms, are crucial since at present, many of the newly developed drugs show initial 
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